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Reperfusion injury is a complex, multifactorial process which is of great importance in
current clinical practice. Two aspects of reperfusion injury following focal cerebral
ischaemia have been studied.
The aetiology of the "no-reflow" phenomenon has been shown to be primarily the adhesion of
activated neutrophils to ischaemic endothelium. The first study undeftaken compared relative
microvascular patency in basal ganglia subjected to 3 hours ischaemia and t hour reperfusion
with basal ganglia subjected to 4 hours ischaemia and no reperfusion. No significant
difference in vessel patency was observed for each vessel size range between the two groups,
suggesting that lengthy periods of focal ischaemia lesult in irueversible microvascular
occlusions in the vascular bed, and thus shorter periods of ischaemia would be more
appropriate time periods for studying this phenomenon.
The synthetic RGD peptide TP9201, which blocks integrin øI16B3, underwent
pharmacokinetic and pharmacodynamic studies in the primate model. The potent effect on
platelet aggregation was confirmed by platelet aggregometry, and a moderate elevation in
template bleeding time was also found. The short half-life of this agent suggests a potential
clinical role in blocking platelet aggregation. However, at the dose used in this model of
focal cerebral ischaemia and reperfusion, 3 of 4 animals infused with this agent sustained
intracerebral haemorrhages into the reperfused basal ganglia. Microvascular patency was
improved but this finding is likely to be artefactual.
The role of endothelium in the modulation of the coagulation system during cerebral
reperfusion was studied using in-situ hybridisation. This technique uses antisense probes to
bind to specific mRNA expressed in tissue sections. This pennits the mRNA of interest to be
localised at a cellular level and semi-quantitated. The technique was developed to the stage
where subcloned probes for Tissue Factor, tissue-type Plasminogen Activator and von
V/illebrand Factor were prepared and used. Hybridisation was achieved, but non-specific
binding proved to be a problem which was not able to be corrected by modification of the
technique. With further development, this will be a powerful tool for studying gene
expression in this model.
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The extent of tissue damage which occurs as a result of ischaemia is dependent upon several
factors: the duration of ischaemia, the level of blood flow during ischaemia and the sensitivity
of the tissues to ischaemia. Upon restoration of tissue perfusion, oxygen and metabolic
substrates are returned to tissues which have been reversibly damaged. However, complex
interactions take place between the blood elements and vessel endothelium, potentially
resulting in an exacerbation of tissue damage. This deleterious effect of return of blood flow
to tissues is termed "reperfusion injury". Repelfusion injury implies that reperfusion with
"unmodified" blood is not an ideal perfusate for ischaemic tissues (Hallenbeck and Dutka,
1990).
Reperfusion injury has been studied most extensively in the myocardium. In 1960 , Jennings
et al suggested that reperfusion may accelerate the development of necrosis in irreversibly
injured myocytes.
Ames and coworkers (1968) showed that following relatively short periods of ischaemia,
localised areas of the brain failed to reperfuse on restoration of blood flow. They
demonstrated this by showing decreased carbon perfusion, and described this finding as the
"no-reflow phenomenon". Ames suggested that increased blood viscosity and reduction of
capillary lumen secondary to perivascular oedema were the most likely causes of this
condition. The "no-reflow phenomenon" is a major focus of the experimental work
undertaken in this laboratory and in this thesis.
The concept that inflammation is a major mediator of tissue injury after ischaemia has been
confirmed by many studies in which anti-inflammatory agents, complement depletion
(Crawford et al, 1988), anti-neutrophil strategies (Engler et al, 1986), and administration of
prostacyclin analogues (Simpson et al, 1987) have been shown to reduce infarct size.
This background discussion of reperfusion injury will cover the lole of the major mediators
of this complex pathological process. Many of the studies discussed wele performed in organ
systems other than brain, and are included as the basic mechanisms appear to be very similar
in each organ system. Much of the available data desclibing endothelial behaviour and the
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role of cell adhesion molecules in l'esponse to ischaemia/reperfusion and inflammation have
been obtained in cell culture experiments.
The roles of cell adhesion molecules and endothelial modulation of coagulation in
reperfusion injury are highlighted because of their relevance to the experimental work
undertaken during this research period.
1.1 Pathophysiology of reperfusion injury in brain following focal
cerebral ischaemia
Vascular endothelium plays a variety of crucial roles in response to physiological and
pathological stimuli. Endothelium is an actively anticoagulant and antithrombotic surface,
maintains cerebral vascular tone by producing sevetal vasoactive factors, and mediates
inflammatory and immune responses.
Vascular endothelial dysfunction is a critical early phenomenon in all forms of
ischaemia/reperfusion (VR). Dysfunction occurs within several minutes of hypoxia in the
cerebral circulation and reperfusion leads to major alterations in procoagulant activil.y,
vascular tone and changes in endothelial adhesion.
1.1.1 Oxygen-derived free radicals
A free radical is a molecule that contains an unpaired electron. These reactive oxygen species
are unstable and hence highly reactive. Generated fi'om the leduction of molecular oxygen,
they include hydrogen peroxide (HZOZ), hydroxyl radical (oOH), superoxide anion radical
(OZ-') and the perhydroxyl radical (HOZ"). They can act as oxidants or reductants.
Free radicals may be generated by mitochondda, activated leukocytes (Britigan et al, 1986),
from endothelial cells following ischaemia/ reperfusion (Jarasch et al, 1986), from tissues
containing activated leukocytes during inflammation (Petlone et al, 1980) and enzymes such
as cyclo-oxygenases or xanthene dehydrogenase (McCord, 1985).
Lipid peroxidation at the cellular membrane level represents a fi'ee radical-mediated chain
reaction that alters or destroys membrane phospholipids. Transition metal ions, palticularly
Fe++ are involved in these redox reactions (Braugher and Hall, 1989).
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Reperfusion is accompanied by the generation of free radicals and other reactive species
which appear to be responsible for tissue damage, rather than tissue acidosis, which may of
itself have a cytoprotective effect in hypoperfusion states (Kitakaze et al, 1988). Since
reperfusion injury requires the re-establishment of flow and delivery of oxygen, free radicals
are likely to play a major role in early endothelial dysfunction in lepelfusion injury and that
damage may be prevented by controlling these radicals. Studies of isolated hearts have
confirmed that free radicals are generated during reperfusion and that cardiac dysfunction
following reperfusion was proportional to the free radical concentration in the perfusate
leaving the heart (Arroyo et al, 1987, Zweier, 1988). Thus oxygen toxicity is a significant
factor in damage previously attributed to lack of oxygen (Levine, 1993).
Generation of free radicals within the microenvironment formed between activated
polymorphs and activated endothelial cells leads to increased vascular pelmeability and tissue
damage. Reperfusion enhances free radical generation by recruiting leukocytes to the
reperfused tissue (Lucchesi et al, 1989).
Injury caused by free radicals can be limited by endogenous superoxide dismutase (SOD),
glutathione peroxidase and catalase (Roos et al, 198[), f]arsacchi et al, 1984)- Studies have
also shown a reduction in free radical generation by the addition of SOD and catalase
(Grammas et al, 1993).
1.L.2 Calcium
Extracellular calcium concentration in areas of injured brain falls fi'om I mMol to less than
0.1 mMol rapidly following injury as calcium moves into ischaemic cells which have lost
their capacity to maintain calcium homeostasis (Young, 1986). Calcium concentration in the
extracellular space then rises over a period of hours due to diffusion of calcium ions from
surrounding tissues. This exposes surviving neurones, which initially were able to maintain
their calcium homeostasis, to a calcium load. "Delayed acceleration" of tissue damage
appears to occur as extracellular calcium levels return to normal in models of ischaemic
neuronal injury.
Ischaemia can also disrupt calcium homeostasis by intelfering with sodium-potassium
ATPase function, resulting in cell membrane depolarisation and intracellular sodium
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accumulation. This can allow calcium to enter cells as sodium is pumped out. In addition,
sequestering mechanisms become impaired within cells, lesulting in calcium movement from
the endoplasmic reticulum into the cytosol. This can result in activation of proteases and
phospholipases (potentially leading to generation of free ladicals), generation of arachidonic
acid metabolites and membrane damage. Reperfusion can also result in an acceleration of
calcium influx into cells by injuring cell membranes and hence increasing permeability
(Murphy et al, 1987). The exact role of cytosolic calcium accumulation in the evolution of
neuronal and myocardial injury after ischaemia remains unclear (Cheung et el, 1986;
Uematsu et al, 1989).
1.1.3. Vessel tone
Vessel tone is influenced by the endothelium. In 1980, Furchgott and Zawadski demonstrated
that endothelial-dependent relaxation of vessels is mediated via endothelium-derived relaxing
factor (EDRF), which was later shown to be nitric oxide (NO). Nitric oxide is generated by
nitric oxide synthetase (NOS), which occurs widely in the CNS and may be activated by
calcium influx in reperfusion injury (Fulchgott and Zawadski, 1980). Nitric Oxide
Synthetase is localised in the neurones and vasculal endothelium (Ross et al, 1990) and will
generate NO from L-arginine. After being leleased by endothelium, NO stimulates soluble
guanyl cyclase in smooth muscle, resulting in increased cGMP and hence relaxation. This is
similar to the effect of nitrate vasodilators (Faraci, 1992). In addition to being a vasodilator,
NO may also influence vascular tone by regulating production of endothelin (ET-l) and
platelet-derived growth factor P (PDGFB) (Kourembanas et al, 1993).
Nitric Oxide also inhibits platelet aggregation by a cyclic GMP-dependent mechanism and
acts synergistically with plostacyclin in this role by incleasing platelet concentration of cyclic
AMP (Moncada and Higgs, 1993). Unlike prostacyclin, NO also inhibits platelet adhesion.
Nitric oxide can rapidly react with superoxide radicals to form the peroxynitrite anion
(ONOO-) which decomposes when protonated to the potent oxidants, hydroxyl radical and
nitrogen oxide (Blough and Zafiriou, 1985). Superoxide dismutase may prevent NO
decomposition by superoxide radicals, which would help maintain normal vasodilatation and
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block thrombosis. SOD can also inhibit the formation of peroxynitrite which could otherwise
decompose to form cytotoxic reactive oxygen species.
Vascular endothelium also produces several vasoconstrictor substances. These include
endothelin (ET-l), which has been shown to be released in vitro in response to thrombin,
adrenalin and calcium ionophore A23187 (Yanagisawa et al, 1988).
Endothelin is a 21-amino acid peptide. Three forms have been isolated, with only ET-1
being produced by human endothelial cells . ET-l is the most potent vasoconstrictor known
and is believed to play a role in cardiovascular homeostasis and possibly pathological states
such as hypertension, atherosclerosis and reperfusion injury (Änggård et al, 1990)
1.1.4 Excitotoxins
The excitatory amino acids, glutamate and aspartate, ate released during ischaemia and the
toxic effect of glutamate exacerbates ischaemic neuronal injuly. These excitotoxins appear to
act via activation of the N-methyl-D-aspaftate (NMDA) receptor, resulting in accumulation of
calcium in the cytosol (Rothman and Olney, 1986; Novelli et al, 1988), the effects of which
have been discussed above.
1.L.5 "No-reflorü" phenomenon
Following relatively brief periods of occlusion of the artery supplying a tissue bed, a
significant proportion of microvessels fail to reperfuse upon restoration of blood flow. The
mechanisms of microvascular occlusions include:
(1) leukocyte plugging of microvessels (Schmid-Schonbein, 1987; del Zoppo et al, 1991);
(2) fibrin deposition in microvessels (Okada et al, 1994):
(3) endothelium becoming procoagulant (Ogawa et al, 1991).
Other potential contributors include endothelial cell swelling (Leaf, 1973), endothelial
luminal membrane tags (Dietrich et al, 1987) and perivascular oedema (Fischer et al,1977).
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1..1.6 Role of leukocytes in reperfusion injury
Leukocytes are stiff, visco-elastic cells which are slightly larger than capillaries and must
deform to pass along capillaries. Leukocytes appear to contribute to the injury initiated by
arterial obstruction. Capillary plugging by granulocytes has been shown to be the mechanism
of microvascular occlusion occurdng in the no-reflow phenomenon in heart and brain (Engler
et al, 1986; del Zoppo et al, 1991; Garcia etal,1994). One adherent leukocyte, trailed by a
rouleau of packed red blood cells appears to occlude each capillary. Obstruction of several
adjacent capillaries may result in underperfusion of individual cells and thus a local hypoxic
environment.
In a recent study of brain infarction in rats, leukocytes (particularly polymorphonuclear
IPMNI) were detected in the capillaries and venules of the ischaemic region as early as 30
minutes after arterial occlusion. The percentage of occluded microvessels increased from
8.57o at 30 minutes of ischaemia to 50.5Vo at 4 hours of ischaemia. The number of
intravascular granulocytes peaked at12 hours after MCA occlusion (seen to be occluding
10.67o of microvessels). However few intravascular PMNs were seen aftet 72 hours . The
number of parenchymal granulocytes peaked at 24 hours, denoting the time-course of
parenchymal infiltration of leukocytes in cereblal infarction (Garcia et al, 1994).
Leukocytes contribute to the endothelial dysfunction which occurs in I/R by several
mechanisms:
1. Adherent, activated leukocytes release reactive oxygen metabolites (particularly
superoxide radicals) at the leukocyte-endothelial intelface. These may inactivate EDRF as
well as having direct toxic effects on endothelium.
2. Activated leukocytes can release a valiety of cytokines including interleukin-l (IL-l)
and tumour necrosis factor (TNF). Tumour necrosis factor can inhibit NO release.
3. Activated leukocytes can damage endothelial cells and increase permeability by
releasing other cytotoxic agents such as proteases, cationic proteins and collagenases (Ma et
aI, 1992).
Using a myocardial model, several studies have demonstrated a telationship between infarct
size following reperfusion and the amount of leukocyte infiltlation (Lucchesi et al,1989;
Lucchesi and Mullane,1986; Romson et al, 1983). Engler et al. (1986) demonstrated
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significant amelioration of "no reflow" and tissue damage in myocat'dium by leukocyte
depletion.
The role of activated leukocytes on infarct size in the cerebral model has not been as
thoroughly studied as in the heart. However Hallenbeck et al. (1986) demonstrated
accumulation of indium-labelled leukocytes in regions of ischaemic brain during the first four
hours post-ischaemia in an air embolism model, although this model cannot be used to
extrapolate directly to the clinical setting. Bednar et al. (1991) demonstrated a significant
reduction in infarct size in neutropaenic subjects in a rabbit model using autologous clot,
whereas thrombocytopaenic animals showed no significant change.
In a rat model of middle cerebral artery occlusion, infiltration of leukocytes into the
ischaemic tissue was noted. Significantly greater infiltration was noted with reperfusion,
using a tissue myeloperoxidase activity assay. Thus celebral reperfusion results in leukocyte
recruitment. This study also demonstrated increased Leukotriene B4 (a chemotactic agent)
receptor binding in a parallel manner, suggesting that binding occul's to receptors located on
neutrophils (Barone et aI, 1992)-
In a recent study of human cerebral infarcts using technetium-99m
hexamethylpropyleneamine oxime 199ma"g¡4PAO)-labelled leukocyte brain single-photon
emission computed tomography (SPECT), leukocyte infiltration was seen in areas of
perfusion defects (scans performed within first week after infarction), persisting at least five
weeks after onset and then declining (Wang et al, 1993).
Leukocyte depletion (Aspey et al, 1989) or leukocyte blockade using antibodies (Mori et al,
1992) have been shown to modify but not reverse the "no-reflow" phenomenon, suggesting
that other factors play a significant role. No study has shown a significant, well-documented
effect on neurological outcome by blockade of leukocyte function, although Vasthare et al
(1990) found better preservation of coftical function in lats subjected to incomplete cerebral
ischaemia (measured by somato-sensory evoked potential activity) in leukopaenic animals
compared to those with normal leukocyte counts.
Adherence of leukocytes and monocytes to the endothelium of the post-capillary venules as
well as recruitment of leukocytes into the adjacent tissue is mediated by several cell adhesion
molecules; members of the integrin family, all 3 selectins and all members of the
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immunoglobulin supergene family. Many of these cellular adhesion molecules are regulated
by multiple, complex mechanisms in response to a variety of cytokines and inflammatory
mediators.
These groups of cell adhesion molecules will be described separately and the mechanisms of
leukocyte-endothelium adherence will be discussed.
1.1.7 Cell Adhesion Molecules and their role in Reperfusion Injury
(a) Selectins
Selectins are a family of membrane glycoproteins, each of which are involved in cell - cell
adhesion events (Bevilacqua et al, 1991). All 3 human selectins comprise a NH2 - terminus
formed by a I20 amino acid lectin domain. This domain is followed by a sequence of 35 - 40
amino acids similar to an epidermal growth factor (EGF) repeating structure . This single
EGF element is followed by a variable number of repeating elements ("consensus repeats")
which are each about 62 amino acids long and are termed "complement binding" (CB)
elements . All selectins are anchorcd to the cell membrane by a single transmembrane region
which is followed by a short I7-35 amino acid tail.
Different mechanisms regulate the presence of each of the 3 selectins at the cell surface
(Vestweber, 1992).
P-selectin
P-selectin (GMP-140, PADGEM, CD62) is constitutively expressed in normal vessels,
particularly post-capillary venules, where it is stored in tl're V/eibel-Palade bodies of
endothelial cells. It is also found in the cr-granules of platelets.
Inflammatory or thrombotic mediators such as thrombin and histamine induce fusion of the
Weibel-Palade bodies to the endothelium within minutes, resulting in neutrophil and
monocyte binding (Sugama et al, 1992). The surface expression of P-selectin in endothelial
cells is transient and returns to basal levels within 20-60 minutes as a result of endocytosis
into new Weibel-Palade bodies (Hattori et al, 1989). It remains on the surface of platelets for
at least t hour after in-vitro activation with thrombin (Geng et al, 1990).
Okada et al (1993) recently demonstrated sustained endothelial explession of P-selectin at 24
hours following focal cerebral ischaemia and reperfusion, and suggested that continued
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generation of thrombin within the microvasculature secondary to exposure of circulating
blood to subendothelial Tissue Factor (TF) may be the cause of this finding.
P-selectin is a receptor for neutrophils and monocytes but not lymphocytes. Expression of P-
selectin on endothelium activated with thrombin or histamine suggests that this adhesion
molecule plays a major role in mediating very rapid binding of neutrophils and monocytes to
venules exposed to these agonists. Activated platelets expressing P-selectin may facilitate
neutrophil and monocyte recruitment to sites of thrombosis or haemorrhage. At sites of
inflammation without haemorrhage, emigrating leukocytes might recruit activated platelets
into tissues by binding to P-selectin.
Circulating plasma P-selectin has been detected in nolmal humans in low concentrations
(=0.1-0.3 pglml) and has been shown to be anti-inflammatory by lesulting in down-regulation
of CD18 - dependent neutrophil adhesion and subsequent respiratory burst. Thus, it may be
of importance in preventing inadvertent activation of circulating neutrophils (Dunlop et al,
r9e2).
The ligands for the selectins appear to be oligosaccharides that are recognised by the N-
terminal lectin-like domains of the selectins (McEver, 1991). Recently, sialyl-Lewis X
(sl.ex), a ligand for P-selectin and E-selectin was shown to dramatically reduce lung injury
generated by Cobra Venom Factor (CVF), when infused into tats. This injury has been well-
characterised as oxygen-derived free radical-mediated, and P-selectin and neutrophil-
dependent (Mulligan et al, 1993).
Endothelial cells stimulated with thrombin or histamine also synthesise the phospholipid,
platelet-activating factor (PAF). After synthesis, PAF is lapidly presented on the activated
endothelial surface, where it can play a key role with P-selectin in PMN adhesion and
activation (Zimmerman et al, 1990; Coughlan et al,1994).
E-selectin
E-selectin is induced on vascular endothelial cells by cytokines such as interleukin-1 (IL-1),
tumour necrosis factor-cr (TNFcr), lipopholysacchalide (LPS) and tequires de novo mRNA
and protein synthesis. E-selectin is expressed within 4 hours of exposure to agonists and is
rapidly down-regulated, attaining basal levels within 16-24 hours. It is not present in normal
endothelium but is found in post-capillary venules at sites of inflammation (Cotran et al,
1986). Sialyl Lewisx appears to be the ligand for this selectin. E-Selectin is a receptor for
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neutrophils and monocytes but not lymphocytes,and has recently been shown to provide
greater strength of rolling adhesions than P-selectin. Slower rolling may lead to a more
localised neutrophil accumulation in adjacent tissues (Lawrence and Springer, 1993).
L-selectin
L-selectin is a calcium-dependent, lectin-like adhesion receptor which is constitutively
expressed on the cell surface of lymphocytes, neutrophils and monocytes. Leukocyte L-
selectin also contains slex, the ligand for P- and E-selectin. Following activation by
chemotactic factors (such as IL-1 and TNF) or pholbol esters, L-selectin is shed within
minutes from the surface of neutrophils. The same stimuli cause an inctease in expression of
the Mac-1 (82) integrin on the cell surface, suggesting that L-selectin may act before the þ2
integrin in the process of adhesion. This is furthel supported by studies showing L-selectin
antibodies inhibit "rolling" of leukocytes in-vivo (von Adrian et al, L992), and that anti-P2
antibodies do not affect rolling but block subsequent firm adhesion of leukocytes to venular
endothelium (von Adrian et al, 1991).
Lawrence and Springer (1991) demonstrated in-vitro that only P-selectin, but not ICAM-1
could support rolling of neutrophils under flow conditions on a lipid bilayer containing the
glycoproteins. Thus rapid explession of L- and P-selectins are probably involved in very
early (reversible) PMN binding while p2 integrins bind to up-regulated ICAM-I at a later
step (Sugama et al,1992).
(b) Integrins
Integrins are heterodimer transmembrane glycoproteins. The cr subunits vary in size between
120 and 180 kilodaltons and are each noncovalently bound to a B subunit (90-110 kdaltons).
Most cells express several integrins. There are currentLy 14 known cr and 8 B subunits
(Hynes, 1992).
Both subunits of integrins are transmembrane glycoproteins with a single hydrophobic
transmembrane segment. The cytoplasmic domains are short (< 50 amino acids) except for
p4. The extracellular domains associate to form the crB heterodimers.
The leukocyte-specific B2 integrins are still referred to by earliel names : o..Lþ2 = LFA-I;
crM B2 = Mac-1.
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Individual integrins can often bind to more than one ligand and individual ligands are more
often than not recognised by more than one integrin. The majolity of ligands are extracellular
matrix proteins involved in cell-substratum adhesion.
Some ligands (such as fibrinogen) can also mediate cell-cell aggregation and some recognise
membrane proteins of the immunoglobulin superfamily (ICAM-l, ICAM-2, VCAM-I) and
mediate cell-cell adhesion (Hynes, L992).
The first integrin binding site to be defined was the Arg-Gly-Asp (RGD) sequence which is
present in fibronectin , vitronectin and several other adhesion proteins. This site is recognised
by crttb Þ3 , aSFt and probably alt cryp integrins . (vide infra page55 ). Different sequences
are recognised by other integrins, eg. o4þI binds Glu-Ile-Leu-Asp-Val (EILDV) and cr2p1
binds Asp-Gly-Glu-Ala (DGEA) in type I collagen. crllb B3 also recognises the sequence
Lys-Gln-Ala-Gly-Asp-Val (KQAGDV) in fibrinogen.
The specificity and affinity of a given integrin receptor on a given cell are not constant. On
resting circulating platelets, integrin ctllb B3 does not bind any of its soluble ligands. If this
were not the case, widespread thrombosis would occur. Unactivated platelets bind to surface-
bound fibrinogen via cx,Ilb p3 and become part of haemostatic events which have already
commenced. However, only after agonist activation of platelets (eg. by thrombin, collagen)
does a¡6 B3 become an effective receptor for fibrinogen or its other ligands (Kieffer &
Phillips, 1990). Activation is associated with a conformational change in the orllb P 3
receptor, and further change occurs with ligand binding.
Activation of leukocytes is required for expression of the ligand-binding activities of the B2
integrins and results in conformational changes in the integrin.
In response to tissue injury, neutrophils and monocytes must attach to endothelium in order to
leave the bloodstream and migrate to the injured tissues. These events involve several
adhesion proteins, amongst which the B2 integrin is central. The first event in this process is
that leukocytes "roll" along the vessel wall. This is mediated by selectins. The integrins on
these "rolling" leukocytes remain inactive until activated by inflarnmatory mediators (eg.
complement C5a, tumour necrosis factor (TNF)).
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(c) Intercellular adhesion molecules
Intercellular adhesion molecule -1. ( ICAM'l).
As previously mentioned, leukocyte adhesion to the endothelium is primarily mediated by the
leukocyre p2 integrin (CD18) binding to its endothelial ligand, intercellular adhesion
molecule-1 (ICAM-1). ICAM-l is a member of the immunoglobulin supergene family and
contains 5 immunoglobulin domains (Springer, 1990). It is constitutively expressed at low
levels on the surface of endothelial cells and is induced and markedly up-regulated by
cytokine stimulation. This process requires RNA transcription and ICAM-1 expression is
maximal at 9-24 hours. The pro-inflammatory cytokines TNF-cr, IL-1, interferon-y and
lipopolysaccharide (LPS) have been shown to up-regulate ICAM-1 expression in endothelial
cells (Pober, 1988; Munro et al, 1989; Wong and Dotovin\-Zis,1992). The ligand for ICAM-
1is the p-2 integrin, LFA-I, which is expressed by neutlophils, lymphocytes and
macrophages.
Using cultured brain microvascular endothelial cells, up to 20 hours of hypoxia did not lead
to ICAM-1 mRNA up-regulation, however up-regulation was noted at 4, 12 and 24 hours of
reoxygenation (Hess et al, 1994). This effect was significantly reduced by N-acetyl-L-
cysteine. Thus free radical generation appears to play a major role in ICAM-1 upregulation in
reperfusion.
Two recent studies have shown that ICAM-I expression is enhanced during myocardial
(Yamazaki et al, 1993) and cerebral (Okada et al, 1993) ischaemia/reperfusion. Furthermore,
two studies (Ma et al, 1992. Yamazaki et al, L993) demonstrated decleased infarct size and
neutrophil infiltration in animals treated with antibodies to ICAM-1.
A second endothelial adhesion molecule, ICAM-2 also binds the cr¡p2 integrin and is
constitutively expressed.
Vascular cell adhesion molecule (VCAM-1) and endothelial leukocyte adhesion molecule
(ELAM-1) are involved in modulating leukocyte-endothelial adhesion. They are normally
not expressed on endothelial cells, but like ICAM-I are induced by proinflammatory
cytokines (Munro et al, 1989).
Two studies showed that monoclonal antibodies to ICAM-I reduce infarct size and improve
neurological outcome in reversible spinal cord ischaemia but not irreversible brain ischaemia
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(Clark et al, 1991; Bowes et al, 1993). In a more clinically lelevant study of transient MCA
occlusion in a rat model, administration of an ICAM-1 antibody prior to reperfusion resulted
in decreased infarct size, decreased polymorph infiltration and imploved neurological
outcome (Zhang et aI, 199 4).
A circulating soluble form of ICAM-I (cICAM-1) has been characterized and levels of
cICAM-1 shown to be significantly lowered in stroke patients (Clark et al, 1993) suggesting
that these patients have altered leukocyte adhesion function.
Pl atelet-endotheli al cell adhesion molecule' 1
Platelet-endothelial cell adhesion molecule-1 (PECAM-1; CD31) is expressed in large
quantities at the junctions between endothelial cells and on the surfaces of monocytes and
polymorphs. Antibodies to PECAM-1 block leukocyte transmigration, suggesting that this
molecule is required for neutrophil transmigration in vivo and thus may have a role in
ischaemia/ reperfusion (Muller et al, 1993, Vaporciyan et al, 1993).
1.1.8 Platelet adhesion and aggregation
Platelet adhesion to vascular endothelium and aggregation can occul'in response to a variety
of mechanical and chemical stimuli. Physiological agonists, such as thrombin, collagen and
ADP may be present at the site of endothelial injury or activation, and stimulate platelet
adhesion.
At levels of shear stress above 60-80 dynes/cm2, stable platelet aggregation can occur without
the need for exogenous agonists (Ruggeri, 1993). Recent studies have established that
fibrinogen is the adhesive protein mediating platelet aggrcgation in a low shear environment
and von Willebrand Factor (vWF) in a high shear environment. High shear stress results in
binding of vWF to GPI6 and this induces a transmembrane influx of calcium ions, resulting
in platelet activation (Chow et aI, 1992). Following platelet activation, the receptor crtrbp3 is
able to bind with soluble adhesion proteins e.g. fibrinogen, and hence mediate plaûelet-platelet
interactions (=ag gregation).
Von Willebrand Factor is required for both platelet activation and platelet adhesion in shear-
induced aggregation. Two distinct sites in the large vWF molecule appear to support this
binding.
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The initial adhesion of platelets in-vivo to a thrombogenic surface involves platelet
interaction with exposed adhesive proteins in the vessel wall. This is quite different to in-
vitro platelet-platelet interactions, due to the differing affinities of platelet receptors for
ligands depending upon whether the particular ligand is immobilised or in solution (Ruggeri,
1993). Similarly, receptor specificity also depends on whether or not platelets are activated.
For example, the crtrbp3 receptor in activated platelets can interact with fibrinogen, vWF,
fibronectin and vitronectin (all containing the RGD sequence). However, on non-activated
platelets, crtr¡Êg can only interact with immobilised fibrinogen (Savage, 1991).
Platelet GPI6 can bind to surface vWF with or without shear stress. Thus the two platelet
receptors GPI6 and crll6p3 are involved in two separate pathways leading to the attachment
of unstimulated platelets to thrombogenic vessel wall which present fibrinogen and/or vWF to
flowing blood (Ruggeri, 1993).
Thrombus formation occurs following platelet-surface contact which leads to platelet
"spreading", a conformation change of the platelet which makes adhesion irreversible.
Spreading involves surface- bound RGD containing ligands with crll6p3 @ytela et al, 1986)'
Platelet activation then results in the binding of additional platelets to the thrombus.
It is possible that additional platelet receptors (such as GPI¿-II¿) and vascular ligands (e.g.
fibrinogen, f,rbronectin and vitronectin) may also play a role.
Integrin crIIUÞ¡ has been shown to serve as a receptor for 4 proteins: fibrinogen (Bennett et
al, 1983), fibronectin (Gardner and Hynes, 1985), von Willebrand Factor (Ruggeri et al,
1982), and vitronectin (Pytela et al, 1986). All 4 proteins contain the RGD sequence, which
is the key recognition domain involved in their binding to platelets. Thrombospondin and
collagen may also bind to the aII6p3 complex. The final common pathway of platelet
activation by several physiological stimuli (eg. thrombin, collagen, ADP and shear stresses),
is the binding of fibrinogen to ctll6p3 (Coller et al, 1983).
Following platelet activation and spreading commencing, the activated platelet becomes a
target for other platelets, and a platelet plug is formed from these platelet-platelet interactions.
Platelet adhesion in the venous circulation is not shear-dependent and thus GPIb and vWF are
not involved. Both activated and unactivated platelets can be involved. Several platelet
integrins, GPIa-IIa (cr2p1 ), ovB3, and aIIbB3 mediate platelet adhesion.
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Platelet-rich thrombi have been shown to be resistant to lysis by thrombolytic agents and have
thus become targets for adjunctive thrombolytic therapy (Falk, 1992). Arterial reocclusion
after effective thrombolysis appears to be largely due to platelet interaction with the affected
arterial surface which stimulates adhesion, aggregation and lethrombosis (Golino et al, 1988).
Platelet-activating factor (PAF)
Platelet-activating factor (PAF) is a high molecular weight phospholipid released from
platelets, neutrophils and vascular endothelium. PAF is involved in leukocyte adhesion to
vascular endothelial cells which have been stimulated with thrombin or histamine.
Endothelial co-expression of P-selectin and PAF appear to maximise PMN adhesion (Lorant
et al, 1991). PAF-receptor antagonists have been shown to decrease leperfusion injury in a
myocardial model (Squadrito et al, 1993; Ioculano et al, 1994).
1.1.9 Current model of neutrophil adhesion to endothelial cells in ischaemia/ reperfusion
Margination and adhesion through specialised receptor molecules are a prerequisite for
leukocyte accumulation in ischaemic and repelfused tissue. Leukocyte adhesion to post-
capillary venules appears to be the major event occuring in the "no reflow" phenomenon
during reperfusion of ischaemic tissues.
Chemotactic factors which may enter the bloodstream by diffusion through the vessel wall
remain close to the endothelial cell, and thus malginated cells ate more likely to become
activated and adherent. This model is based on the leviews of Butcher (1991), and von
Adrian and Arfors (1993).
Step 1. Reversible "rolling" of leukocyte mediated by selectins.
Within minutes of tissue injury, neutrophils "roll" along vessels in areas of tissue injury or
ischaemia. "Rolling" almost certainly involves lapidly leversible receptor-ligand interactions
of neutrophils to post-capillary venular walls and is mediated by selectins. This initial
adhesion event involved selectin binding to oligosacchalide ligands such as sialyl Lewisx
(sl-ex). Neutrophil L-selectin is constitutively explessed at high levels on circulating non-
activated neutrophils and mediates the binding of neutrophils to cytokine-activated
endothelial cells (EC). "Rolling" slows the passage of neutrophils thlough capillaries and
post-capillary venules, allowing the neutrophil to be exposed to the endothelial ."ll ,urfo..25
where more permanent binding can occur. Rolling appears to be essential for successful
neutrophil-EC interaction.
Systemic treatment with antibodies to L-selectin (but not with antibodies to B2 integrins) has
been shown to decrease rolling in mesenteric venules by 70-80Vo in labbits (von Adrian et al,
1991). Similarly, human neutrophils injected into rabbit superior mesenteric artery roll in
inflamed post-capillary venules via an L-selectin dependent mechanism (von Adrian et al,
1992). The endothelial selectins, E- and P-selectin also appear to support rolling. These
selectins are induced on ischaemic (or inflamed) endothelium and bind sl-ex and related
surface carbohydrate ligands expressed on leukocytes in vitro (Lawrence and Springer, 1991;
Bevilacqua et al, 1989).
Thus there appears to be a bi-directional lecognition mechanism of leukocyte rolling. L-
selectin can interact with endothelium independent of endothelial sl-ex by recognising an
endothelial ligand (a carbohydrate) and simultaneously presenting sl-ex to vascular selectins.
Step 2. Activation of rolling neutrophils in the vascular lumen.
Neutrophils which have been activated by chemoattractants shed L-selectin from their cell
surface (Kishimoto et al, 1989). The B-2 leukocyte integrin, Mac-1, is rapidly upregulated
during neutrophil interactions with inflamed venular endothelium. The specific factors
responsible for activation of rolling neutrophils are not well-characterised. The release of
histamine and thrombin from mast cells, and cytokines (IL-1 and TNF-o) from endothelium,
lead to release of chemotactic cytokines such as IL-8 and increased explession of E-selectin
and ICAM-I.
Step 3. Stable binding to the endothelium involves the activation-dependent þ2
integrin, Mac-l (CDllb, CD18).
Leukocyte p2 integrins, in particular Mac-I, are believed to be unable to bind their
endothelial ligand until they ale activated. Cell activation appears to result in a temporary
conformational change of the molecule. Following activation, exposul'e to an inflammatory
stimulus results in firm leukocyte attachment to the endothelium via Mac-1 to ICAM-1
binding. Stable binding of leukocytes to endothelium can only take place when the
leukocytes are "rolling". Neutrophils lacking L-selectin or sl-ex roll poorly and cannot stick
in response to chemotactic stimulation (von Adrian et al, I992b). However, Arfors et al
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(1937) showed that anti-p2 antibodies allowed release of rolling neutrophils to the circulation,
by preventing the arrest and stable attachment of rolling cells.
Activation-dependent adhesion via leukocyte integrins is stable under physiological shear
forces and sustained for several minutes, but is eventually reversible.
This multi-step model of recognition permits a given receptor to be involved in more than one
recognition event whilst still maintaining specificity. Both selectin-dependent early adhesion
and activation-induced p2 integrin function are essential for firm neutrophil attachment to
ischaemic endothelium (von Adrian and Arfors, 1993).
1.1.10 Activation of the blood complement system
Activation of the complement system by the classic or alternative pathways results in the
production of the pro-inflammatory mediators C3a, C4a and C5a, which recruit leukocytes to
sites of tissue injury (Fernandez et al, 1978). C5a has also been shown to induce cytokine
synthesis and release from leukocytes and monocytes (Ember et al,1994; Scholz et al, 1990;
Okusawa et al, 1987; Okusawa et al, 1988).
1.1.11 Cytokines
Cytokines are polypeptides or glycoproteins of low molecular weight. Most cytokines are not
stored as preformed molecules; hence their production requires new gene transcription and
translation. Transcription is dependent upon an unstable mRNA, allowing for tight control of
expression.
All cytokines exert their effect by binding to specific cell-surface receptors. Their ability may
also be modulated by expression and shedding of cytokine cell-surface receptors. Vascular
endothelial cells are both a target and a source of cytokines.
In a rat model of coronary ischaemia/ reperfusion, tumour necrosis factor (TNFcr) was not
detected during ischaemia of one hour duration, but was expressed following reperfusion.
Antibodies to TNFcr resulæd in decreased CPK and myeloperoxidase activity (Squadrito et al,
1993).
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Ischaemia/reperfusion of rat hind limb has been shown to lesult in local as well as systemic
effects: increased muscle permeability and intramuscular haemorrhage, and increased lung
permeability, haemorrhage and increased tissue myeloperoxidase activity reflecting white cell
accumulation in the lung tissue. Within 60 minutes of reperfusion, increased levels of TNFcr,
IL-1 and IL-6 were noted. Antibodies to TNFo protected the lung and skeletal muscle from
these injuries, confîrming the role of cytokines in mediating local and remote effects of tissue
injury (Seekamp et al, 1993).
Interleukin-1
Interleukin-1 (IL-1) has been shown to induce endothelial synthesis of procoagulant Tissue
Factor, and increased adhesiveness of leukocytes to endothelial cells, which suggests a major
role in reperfusion injury as well as inflammation (Bevilacqua et al, 1985).
Hypoxia induces IL-l mRNA and release of IL-l by cultured endothelial cells. IL-l
stimulates induction of ELAM-1 and ICAM-l on endothelial cells, supporting the hypothesis
that cytokine production by hypoxic endothelial cells can contribute to the host response in
the pathogenesis of ischaemic vascular injury (Shreeniwas et al, 1992).
Brain IL-IP mRNA has been shown to be elevated acutely after pelmanent focal ischaemia
(particularly in hypertensive rats), suggesting that this potent cytokine may have a role in
brain damage following ischaemia. Expression is up-r'egulated within one hour of ischaemia
and there is a major up-regulation from 6 houls to 5 days following onset of brain ischaemia
(Liu et al, 1993). The degree of up-regulation was related to the severity of neurological
deficit, but the cellular origin of this cytokine was not clarified in this study (in situ
hybridisation would be required to obtain cellulat localisation of expression). Transient focal
cerebral ischaemia has also been shown to up-regulate IL-1 mRNA (Minami et al, 1991).
The probable consequences of up-regulation of IL-18 mRNA and subsequent production of
IL-1P include activation of microglia and astrocytes and transformation of endothelium to a
prothrombotic state that predisposes to thrombosis.
Interleukin-8
Interleukin-8 (IL-8) is secreted by activated macrophages and glanulocytes and by endothelial
cells. Both forms stimulate pro-inflammatory responses in neutrophils, including superoxide
radical production, adhesion and chemotaxis via binding to cell surface t'eceptor coupled to
intracellular signal transduction pathways (Holmes et al, 1991). However, IL-8 decreases
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attachments of granulocytes to stimulated human umbilical vein endothelial cells (HUVECs)
(Gimbrone et al, l9S9). IL-8 given intravenously reduces granulocyte recruitment to
inflammatory sites induced in rabbit skin (Hechtman et aI, I99l) and anti-inflammatory
effects have been observed in a model of myocaldial I/R in the labbit (Leferet al, 1991) (=
LAI3 effect).
IL-8 (like other chemoattractants) induces rapid shedding of L-selectin from human
granulocytes and thus may impair leukocyte rolling due to loss of L-selectin. This may be
responsible for decreased granulocyte recruitment in vivo (Ley et al' 1993).
l.l.l2 Heat Shock Proteins
Heat shock proteins play an important role in protecting cells against ischaemic injury. In a
rat model of cerebral ischaemia, fixed ischaemia resulted in moderately increased Heat Shock
Protein 70 (hsp70) and cfos mRNA expression. However reperfusion for 2 hours following 1
hour of ischaemia resulted in intense hsp70 mRNA expression, suggesting reperfusion
triggered expression in previously ischaemic regions (Welsh et tl, 1992). Similarly, An et al.
(1993) demonstrated induction of cfos and cjun family rnRNA immediately after reperfusion
of focal cerebral ischaemia, peaking at 60 minutes.
Other studies have shown hsp70 mRNA and hsp70 are detected in endothelial cells, even in
the ischaemic infarct zone, suggesting that inflammatory cells of non-neuronal origin may
account for cytokine mRNA expression (Kinouchi et al, 1993). Thus immunohistochemical
staining, Northern blot RNA assay and in situ hyblidisation ale needed to fully clarify the
cellular origin of up-regulated cytokine and stress protein expression in VR.
1.1.13 Endothelial modulation of the coagulation system in ischaemia/reperfusion.
Anticoagulant function of endothelium
The vascular endothelium is an actively anticoagulant and antithlombotic surface. A
glycocalyx "carpet" lies on the luminal surface of endothelium, regulating access to surface
receptors. The glycocalyx is extremely sensitive to hypoxia and its disruption may be the
first sign of endothelial cell damage. There appears to be a relationship between preservation
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of the glycocalyx and endothelial cell integrity (hence capillary permeability) (Ward and
Donnelly, 1993).
The thrombomodulin - protein C - protein S system contributes to the anticoagulant function
of endothelium. Thrombomodulin binds and alters thrombin resulting in fibrinogen no
longer being its substrate, but instead the thrombomodulin-thrombin complex activates
protein C which inactivates factors V and VII as well as tissue- type plasminogen activator
inhibitor.
Tissue-type plasminogen activator (tPA) is also released from the endothelium.
Tissue-type pl asminogen activator
Tissue-type plasminogen activator is a serine protease which catalyses the conversion of
plasminogen to active plasmin by hydrolysis of the peptide bond between Arg 560 and Val
561 in the plasminogen molecule. Tissue- type plasminogen activator is produced as a527
amino acid polypeptide, which displays homology with parts of other proteins. It is built
from 5 domains. From the N-terminus end, it consists of a finger domain (homologous to a
similar fibronectin domain), a growth factor domain, two kringle domains (originally found in
prothrombin) and a protease domain (Pennica et al, 1983).
Regulation of tPA synthesis appears possible via protein kinase C, cAMP and steroids, and
may be associated with the regulation of type-l plasminogen activator-inhibitor (PAI-1)
synthesis.
Endothelium releases tPA continuously and acutely in response to stimulating factors.
Vascular endothelial tPA activity has been demonstrated in smaller veins and venules and in
the vasovasorum of larger veins and arteries, and in the pulmonary vessels (van Hinsbergh,
1e88).
Utilizing in-situ hybridisation techniques on a panel of l4 tissues from primates, tPA mRNA
was demonstrated in the endothelial cells of small venules and in the adventitia of larger
vessels (Gordon et al, 1989). Acute release of tPA occuts in response to a variety of stimuli
such as products from platelet and coagulation activation (Emeiss, 1988). There appears to be
a significant intracellular and extracellular pool (on binding sites on the endothelium) of tPA.
Tissue-type plasminogen activator lelease associated with coagulation sytem activation
occurs both locally and downstrcam of the site of fibrin folmation.
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Fibrinolysis depends not only on the supply of tPA in the circulation but also on the local
endothelial tPA activity in response to stimuli such as reaction products from coagulation
e.g. activated Xa (Giles et al, 1939). Local release provides high concentrations of tPA at the
site of fibrin formation. Only tPA incorporated during fibrin formation is an efficient
fibrinolysis activator, having relatively low activity in pre-existing fibrin clots.
Procoagulant functions of endothelium
In response to a variety of stimuli, including mechanical trauma, ischaemia and inflammation,
endothelium can become procoagulant.
The procoagulant behaviour of endothelium includes:
(1) expression of plasminogen activator inhibitor-l (PAI-l)
(2) expression of binding sites for factors IX and X and platelet adhesion molecules.
Factor X has been shown to be induced in endothelial cell culture exposed to
hypoxia, supporting a role of hypoxia in inducing endothelial procoagulant activity
(Ogawa et al, 1991).
(3) down regulation of anticoagulant mechanisms
(4) expression of tissue factor (TF) which activates the extrinsic pathway of coagulation
on exposure to factor VIVVIIa.
Plasminogen activator inhibitors
Type I plasminogen activator inhibitor (PAI-1) is the physiological inhibitor of both tissue-
type and urinary-type plasminogen activators. It is a single chain glycoprotein consisting of
379 amino acids (Erickson et al, 1984). Unbound PAI-1 has a sholt half-life (7 minutes in
rabbits lColucci et al, 1985]), however binding to vitronectin stabilises PAI-1 in its active
conformation and thus increases its half-life (Loskutoff et al, 1989).
PAI-1 is derived from endothelial cells, hepatocytes and alpha granules of platelets (Erickson
et al, 1984), and its activity is increased by interleukin-1 (Nachman et al, 1986), TNF, TGFP
and LPS (Sawdey and Loskutoff, 1991). Some disease states have demonstrated increased
PAI-I expression, e.g. renal disorders, which may be mediated by endotoxin (Keeton et al,
1993). Cytokine release in ischaemia/ reperfusion may result in elevated PAI-1 levels and
thus contribute to increased endothelial procoagulant activity and increased thrombin
formation in vessels.
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Activation of the coagulation system
Formation of thrombin is central to the coagulation cascade. The most important source of
thrombin quantitatively is platelets. Endothelium is also capable of generating thrombin
which could prime the platelets to release their stores. However, on "resting" endothelium
and in the absence of TF expression, endothelial thrombin is inactivated by antithrombin trI
or bound by thrombomodulin. If cytokines or other mediators cause down-regulation of
thrombomodulin and up-regulate expression of TF, coagulation occurs rapidly.
Tissue factor
Tissue Factor (TF) is a 47 kDalton membrane-bound glycoprotein.
It is the cofactor for factor VII and VIIa, which in its absence have no activity. Binding is
calcium-dependent. The TF-VIIa complex causes the activation of fators IX and X. Rapid
preferential activation of factor VII bound to TF by trace amounts of Xa is a key early step in











Figure 1.1 Activation of the extrinsic pathway:
(based on Rao and Rappaport, I 988)
Tissue Factor is present in the plasma membrane of many cells and is found in the adventitia
and to a lesser extent, the media of normal blood vessels (Wilcox et al, 1989; Drake et al,
1989).
In cerebral tissue of primates, TF was found most prominently in cerebral cortex, and in




demonstrated to be associated with non-capillary microvessels in the basal ganglia and cortex
(del Zoppo et al, 1992). A study in this laboratory using a monoclonal antibody to TF (ff9-
684) in focal cerebral ischaemia and reperfusion showed a significant increase in
microvascular patency in the 7.5-30 pm and 30-50 pm diameter vessels consistent with
blocking exposed TF in reperfused post-capillary venules and larger venules (Thomas et al,
1993). In a rabbit large vessel injury model, TF antibody decleased the incidence of platelet-
mediated arterial thrombosis (Jang et al,1992).
These findings suggest that microvascular thrombosis may occur as a lesult of exposure of
blood to subendothelial tissue factor in situations of vascular injury or events resulting in
increased endothelial permeability (such as ischaemia/reperfusion).
Using cultured vascular endothelium, a number of cytokines, including TNF (Nawroth and
Stern, 1986; Bevilacqua et al, 1986), IL-l (Nawroth et al, 1986; Bevilacquaetal.,1936) and
bacterial lipopolysaccharides (LPS) have been shown to induce TF activity (Colucci et al,
1983; Moore et al, 1986). Bevilacqua et al (1986) showed that the effects of TNF and IL-1
were additive in human vascular endothelium. The peak procoagulant response was noted 4
hours after cytokine stimulation.
The mechanism of TF activation appears to be due to increased mRNA levels which were
detectable within 30 minutes of exposure to LPS and maxim al at 2 hours. However, this
observation was felt to be largely due to increased TF mRNA stability rather than an
increased rate of transcription (Crossman et al, 1990). Maximal levels in response to TNF
have been noted at 4 hours (Conway et al, 1989).
Inflammatory stimuli (e.g. LPS) have also been shown to induce TF expression in
macrophage/monocytes via gene transcription within 15 minutes, peaking at 2-4 hours
(Mackman et al, 1993). Thus explession of TF on the surface of monocyte/macrophage cells
and exposure of subendothelial tissue would lead to folmation of the TF-factor VIIa complex
and hence thrombin generation and fibrin formation.
Tissue factor mRNA expression in cerebral tissue has been noted in astrocytes in the cortex
and Bergmann glia (cerebellum). Endothelial cells did not express TF under resting
conditions or following stimulation with LPS, suggesting that endothelial cells in vivo
respond differently to cytokine stimulation than cultuled endothelial cells (Mackman et al,
1993). The role of astrocytes in the formation of the tight junctions between endothelial cells
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that form the blood-brain barrier suggests that TF may form a "haemostatic envelope" around
vessels in the brain, which can activate coagulation when vascular integrity is disrupted
(Drake et al, 1989)
No data are available using in-vivo models to clarify whether TF is up-regulated during VR
in brain, or whether medial and adventitial TF is exposed to circulating blood elements during
VR, thus providing the basis for the in situ hybridisation expedments undertaken.
Thrombomodulin
Cytokines and LPS also reduce thrombomodulin (TM) activity (Moore et al, 1986; Nawroth
et al, 1986) by suppressing transcription (Conway and Rosenbelg, 1989). Thrombomodulin
is a membrane-bound co-factor which causes the activation of Protein C (APC) in the
presence of thrombin. APC with its co-factor, Protein S, has an inhibitory effect on
coagulation by cleaving VIIa and Va. Thrombomodulin has not been demonstrated in
cerebral microvasculature. If demonstrated in cereblal microvasculature, these responses
would facilitate the rapid conversion of microvascular endothelium from anticoagulant to
procoagulant status following cytokine or hypoxic stimulation duling ischaemia/ reperfusion.
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Chapter Two
Study of microvascular patency following 4 hours of focal cerebral
ischaemia and no reperfusion in comparison to 3 hours of ischaemia and
one hour of reperfusion.
2.1 Aims
A considerable amount of microvascular patency data are available for focal ischaemia
followed by periods of reperfusion. However, no patency data has been obtained in focal
cerebral ischaemia and no reperfusion.
Obtaining a data set of microvascular patency following 4 hours of ischaemia and no
reperfusion would be useful in several ways:
(1) To compare the effects of t hour of reperfusion compared to an extra hour of
ischaemia on microvascular patency.
(2) As a baseline for further studies involving pharmacological agents which may modify
intravascular thrombosis thus affecting patency and potentially modifying infarct size.
2.2 Null Hypothesis
The null hypothesis of this study states that thele is no difference in relative microvascular
patency in ischaemic basal ganglia between animals undelgoing 4 hours middle cerebral
artery (MCA) occlusion and those undergoing 3 houls middle cerebral artery occlusion with 1
hour reperfusion.
2.3 Materials and methods
2.3.1 Focal cerebral ischaemia /reperfusion model
The focal cerebral ischaemia/reperfusion model described below has been used extensively in
this laboratory for two major types of studies: (1) immunohistochemisû'y, and
(2) microvascular patency studies.
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Adolescent male baboons (Papio anubis/cyanocephalus) weighing between 7.5 and 10.0 kg
were used in these studies. These animals were observed to be free of disease during
mandated United States Federal and State Government quarantine periods (60 days in total).
All procedures were approved by the Animal Research Committee of Scripp's Research
Institute and were performed in strict adherence to the standards published by the National
Research Council (the Guide for the Care and Use of Laboratory Animals), the National
Institutes of Health policy on Humane Care and Use of Laboratory Animals and the USDA
Animal Welfare Act.
The techniques currently used in this model are closely based on those previously reported
from this laboratory (det Zoppo et al, 1991). General anaesthesia was induced in the subjects
by an initial sedating dose of ketamine, followed by intravenous pentothal sodium (10 mg/kg
bolus and 10 mg/kg/hr) and halothane. Endotracheal intubation was then performed. Under
antibiotic cover, a right transorbital approach was made to the internal carotid and middle
cerebral arteries. This procedure involved removal of the medial sphenoid wing. A small
inflatable silastic balloon assembly (Mentor Corporation, Goleta, California) was placed
around the right middle cerebral artery (MCA) proximal to the oligin of the lenticulostriate
arteries. The device was fixed in position using viclyl ties in such a way that the MCA sat
between the inflatable balloon and a coated wire frame. The device was fixed in position
using methylmethacrylate and the connecting tube and plug wele placed subcutaneously in a
tunnel near the apex of the head.
Postoperative recovery was closely monitored and typically the subject was fully conscious
within 2-4 hours. The animals were closely observed and assessed neurologically to ensure
that there \'/as no deficit related to the procedure. Observation was continued for a period of
6-7 days prior to any further procedure being performed. A normal neurological score
(N=100), using the scale devised by Spetzler et al (1980) (see Appendix I) was observed prior
to proceeding to middle cerebral artely occlusion.
In focal ischaemia procedures, occlusion of the right middle cerebral artery was performed by
inflation of the occlusion catheter. The awake baboon was seated in a chair and the
subcutaneously placed plug and tube were exposed under local anaesthesia (l%olignocaine).
The appropriate volume of fluid (approximately 150 pls) was then injected into the device.
The tubing was then clamped while the plug was reinserted into the device. No distress or
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agitation was noted in any animal as the neurological deficit became apparenL The skin
incision was then closed. Neurological scorcs were pelformed at 10 minutes, t hour and each
subsequent hour. In all subjects, a definite neurological deficit was noted within 10 minutes.
Full blood counts were obtained at 0, 60, 180 minutes of ischaemia and at intubation prior to
perfusion. In procedures in which reperfusion was performed, the fluid injected into the
device was aspirated at the appropriate time.
Approximately 15 minutes prior to the end of the period of reperfusion, each animal
underwent perfusion-fixation under general anaesthesia. Intubation was peformed under
ketamine which was followed by pentothal (10 mglkg). The subject was then mechanically
ventilated.
In animals not undergoing a period of reperfusion, the MCA occlusion device was deflated
just prior to perfusion of the brain. A median sternotomy was performed and the descending
aorta and inferior vena cava exposed. These vessels were both clamped and the right atrial
appendage was vented. Cerebral perfusion-fixation was commenced by left ventricular
cannulation and infusion of a chilled solution (4'C) of plasmalyte at a pressure of 160-200
mm Hg. The solution contained 25 grams/litre of bovine serum albumen adjusted to 340
mOsm with NaCl to which was added 2500 units of hepalin / litle and 7 pM Na+
nitroprusside. Four litres of perfusion fluid were infused over a 5 minute period.
(a) Vessel Patency Studies
Subjects used for vessel patency studies (i.e. 4 hout ischaemia and TP9201 study ) were
perfused via the left ventricular cannula with plasmalyte solution followed by chilled carbon
suspension in paraformaldehyde (India ink, Pelican AG, Hannover, Germany in 4Vo
paraformaldehyde). Perfusion pressure was maintained at 180-200 mmHg for this procedure
due to greater fluid viscosity. Seven litles wele perfused ovet' a 15 minute period. This
technique resulted in brain fixation by the paraformaldehyde and carbon tracer filling of all
patent vessels.
The brain was then removed and underwent a pedod of 7 days fixation in AFA solution (877o
ethanol, lÙVo of 47o formaldehyde and37o glacial acetic acid), plior to coronal sectioning at 5
mm intervals.
Visual inspection of the brain was undertaken for macroscopic evidence of decreased
perfusion and evidence of haemorrhage. Photographs of coronal sections were taken and
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diagrammatic representations made. Blocks were then cut of identical sites of both basal
ganglia and temporal cortex. The left side (not ischaemic) served as a control. Twenty
consecutive sections were cut at 10 pm thickness by Hector Herreira (Department of
Cytology, Sharp Hospital, San Diego, California) and stained with basic fuschin/methylene
blue.
(b) Immunohistochemical studies
Subjects used for immunohistochemical studies underwent blain perfusion with chilled
plasmalyte solution, as described previously, and then rapid r..rnouot of the entire brain and
upper spinal cord from the cranium. The brain was then kept on ice and sliced coronally in 5-
6 mm thick sections. Blocks of right and left basal ganglia, temporal cortex and parietal
cortexwerecut- eachblock= 1x 1x0.5 cm. Theblocks wereplacedin acassette,covered
with OCT and snap frozen in pentothal containing dry ice. These sections were then stored at
-70oC for sectioning and subsequent immunohistochemical staining. These
immunohystochemical experiments were the projects of Y. Okada M.D. and G. Hamann
M.D. and are briefly described in Appendix 4. The staining and counting of sections was
undertaken by these colleagues.
(c) Measurement of Microvascular Patency
The sections of brain perfused with india ink were viewed to exclude artefact and adequacy of
staining and vessel filling. Evely third section (30 pm apart) of both left and right basal
ganglia of each animal was then counted . Thus 7 sections were counted from both basal
ganglia of each animal.
Vascular patency was quantified using the VIDAS video imaging system. A Hamamatsu
C2400 video camera (Hamamatsu, Japan) was connected to a light micloscope (Carl Zeiss,
Munich, Germany) with a powered stage. The imaging system measured the number and
minimum diameter of all vessels containing India ink in the fields studied. Sections were
viewed to ensure good perfusion and absence of artefacts. The arca of study was selected to
contain the maximum proportion of grey matter, as the white matter contains several-fold
fewer vessels than adjacent grey matter. The system measured 90 fields (9x10) at 200 times
magnification in a 5x5 mm area of each slide.
A minimum of 2000 vessels per left basal ganglia were measured, although generally 3000-
5000 vessels were counted in the 7 slides, and a size and fi'equency profile obtained.
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The data were converted to a Maclntosh compatible folmat. Using the "Wingz" programme
on a Quadra 700 computer, the data derived from each section were sorted into ascending
diameter measurements. Values less then 4 pm were deleted and the remaining values put
into bin ranges of 4-7.5 pm (representing capillaries), 7.5-30 pm (representing precapillary
arterioles and post-capillary venules), 30-50 pm (larger arterioles and venules) and 50-100
pm (arterioles and venules - few vessels were measured in this category).
Using the data obtained for the sections of left and right basal ganglia, a percentage reflow
was able to be calculated at each vessel size range for each animal.
The reflow for each size range was calculated as the total number of vessels counted in 7
sections in the particular size range on the right (ischaemic) side divided by the total number
of vessels counted in 7 sections in the particular size range on the left (control) side,
expressed as a percentage.
The actual number of vessels in the control side varied quite significantly between subjects,
and in particular several brains contained vessels which appeared to be helical in orientation,
resulting in a greater number of vessels being counted. This appearance was also noted upon
examination of cortical blocks in the same animals.
2.4 Reproducibility of video imaging system
Reliability and reproducibility data have been pleviously reported with this video-imaging
system (del Zoppo et al, 1991). Reproducibility of the measurements was assessed by
recounting eight separate microvessels 4-24 ¡tm in minimum diameter on twenty occasions.
These vessels were independently measured on a 10 pm reticule. Coefficients of variance
were 0, 0.18, 0.47,0.54,0.89, 5.46,5.74, and 5.93% and were independent of vessel
diameter.
Reliability of microvascular patency was determined by counting 90 fields in 2O successive
sections (as previously described) of left basal ganglia of 2 specimens. The distribution of
vessel diameters from 4 to 100 pm showed no significant diffelence between sections up to
50 pm apart.
Sections were counted from the same subject alternately from left and right basal ganglia by
one individual. The contrast and intensity of the video-imaging system was carefully
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adjusted to ensure that only carbon-filled vessels were counted and that pyknotic nuclei were
excluded.
2.5 Results
The four animals undergoing 4 hour middle cerebral artery occlusion and no reperfusion
(MCAO) were#176,202,207, and 175. The animals which had previously undergone 3 hour
middle cerebral artery occlusion and t hour of reperfusion (MCAO/R) were #1O7,I30, I42,
and 144.
2.5.1 Clinical findings
Clinical and haematological data are shown in Tables 2.1 and 2.2.
Subjects in both groups underwent MCA occlusion device placement 7 days prior to the
experiment and recovered with no neurological deficits (N=100). Following MCA occlusion,
all subjects sustained a persisting neurological deficit (N=46, 42,27,76; mean 48) consistent
with a focal cerebral ischaemic event. The previously studied MCAO/R subjects sustained
similar persisting neurological deficits (N=47, 55, 81, 81; mean 66).
Baseline white cell count was 8 500, 8 800, 9 800, and 10 000 per pL (mean 9 300) in the
MCAO group, which became elevated during the ischaemic event. Similarly, the MCAO/R
group had baseline white cell counts of 11 600, 13 000, 13 300 and 14 100 (mean 13 000)
which also became markedly elevated during the ischaemic peliod.
2.5.2 Macroscopic frndings
Photographs of coronal sections of brain ate shown in Appendix 2.
Gross examination of the MCAO/R subject btains demonsttated one specimen with a small
petechial haemorrhage only. All subjects had evidence of right cotpus striatal perfusion
defects manifest by pallor in the right basal ganglia. In the MCAO group a single animal
(#175) had a large haemorrhage involving the entire right basal ganglia. This is evident from
the photograph. Because of the presence of the extensive haemorrhage, it was not possible to
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quantitate microvascular patency, so that this specimen was temoved from the data
acquisition. Two other subjects had petechial haemorrhage, but all three of the remaining
subjects had evidence of pallor to carbon tracer in the right basal ganglia.
2.5.3 Microvascular fi ndings
Tables 2.3 to 2.6 detall the number of patent microvessels (manifested by those containing
carbon tracer) for the given microvascular sizes on each counted slide. The microvessels of
4.0 to 7.5 pm diameter represent capillaries, 7 -5 l.o 30.0 pm postcapillary venules and
precapillary arterioles, those 30.0 to 50.0 pm small arterioles and venules, and 50.0 to 100.0
pm larger arterioles and venules. The microvascular size groups lepresent cumulative counts
from each of seven slides 30 pm apart in each of the left and right basal ganglia for all
specimens. The total numbers of vessels counted for each slide are noted in the last column
of each table.
3 hour ischaemia / t hour reperfusion cohort
Tables 2.5 and 2.6 document the number of vessels counted in each slide of this group of
subjects.
Percentage reflow for each size range was calculated as number of patent microvessels in
ischaemic basal ganglia divided by number of patent microvessels in control basal ganglia for
the same microvascular size.
A mean 45Vo reflow was observed in microvessels 4.0 to 30.0 ¡tm diameter, with higher
reflows evident in larger vessels. These were due to the smallel number of 50.0 to 100.0 pm
vessels for counting in each section. Those observations were consistent with previous
observations in other cohorts. A more detailed examination of the data demonstrates that two
subjects (#142, #t44) had a 28 and 47 7o rcflow in the 4.0 to 7.5 pm range, but a >607o reflow
in 7.5 to 30.0 pm range. Two remaining subjects (#130, #107) had a 44Vo and 64Vo reflow in
the 4.0 to 7.5 pm range with only I7 to 29qo in the 7.5 to 30.0 pm range. This suggests a
clustering around 7.5 pm in those animals. The ovetall mean leflow was found to be 45.8 +
12.67o in the 4.0 to 7.5 pm range and 44.6 ! 22.17o in the 7.5 to 30.0 pm vessel group (see
TabIe2.7).
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Figure 2.1 shows lelative miclovessel patency for each animal and Figure 2.3 shows overall
patency.
4 hour ischaemia / no reperfusion cohort
Vessel patency is given on Tables 2.3 and2.4 and summary data in Table 2.7. Microvascular
patency was assessed in 3 subjects (one excluded due to haemorrhage involving all of right
basal ganglia).
In the 4.0 to 7.5 pm (capillary) range, mean patency was 54.7Vo (standard deviation I3.lVo) a
mean of 6,(X)0 vessels were counted on the control side in this size range. In the 7.5 to 30.0
pm range (post-capillary venules and pre-capillary arterioles), mean patency was 69.l%o
(standard deviation 26.67o), with a mean of 5,900 vessels counted on the control side. In the
larger vessel categories, Vo rcflow was 94Vo (30-50 pm), 1I5Vo (50-l00pm) and I877o (>100
pm), but the number of vessels in these categories is too small for statistical analysis. At each
vessel size category, no statistical difference in miclovascular patency was noted between the
3 hour ischaemia/1 hour reperfusion and the 4 hour ischaemia subjects (Figure 2.2).
2.6 Discussion
A considerable body of information regarding the "no-reflow" phenomenon has been
undertaken in the laboratory in which this reseatch fellowship was undertaken. A
computerised video-imaging system has been utilised to calculate microvascular patency
accurately. These patency studies have been undertaken exclusively using a 3 hour ischaemia
followed by I hour of reperfusion paradigm.
The results of this study demonstrated that focal cerebral ischaemia of 3 hours duration
followed by reperfusion, results in a relative microvessel patency in the ischaemic basal
ganglia compared to the left (nolmal) side of 467o for the 4 - 7.5 pm diameter vessels, 457o
for 7.5 - 30 pm vessels and767o for the 30 - 50 pm diameter vessels. This was consistent
with previous results. The relative microvascular patency following 4 hours of ischaemia
were 557o for the 4.0 - 7 .5 pm diameter vessels, 697o for the 7.5 - 30 pm vessels and 94Vo for
30 - 50 ¡rm diameter vessels. The minimum number of vessels counted in the control basal
ganglia of one animal was 3,973 vessels.
42
There was no significant difference in patency between these 2 study groups at any vessel
size range.
Previous experiments using this 3 hour ischaemia I t hour reperfusion model have
demonstrated a significant improvement in reflow in the 7.5 to 50 pm vessel size range,
when the ischaemic brain is reperfused with blood containing Tissue Factor antibody
(Thomas et al, 1993).
Similarly, using anti CD18 antibodies (blocking leukocyte adherence to endothelium), a
significant increase in microvascular patency was found in the 7.5 to 50 pm vessel range
(Mori et al, 1992). Neither study demonstrated a significant improvement in capillary
patency and both studies found a mean 807o patency in the 7.5 to 30 pm vessel range.
These previous studies of Thomas et al, and Mori et al, demonstrated that reperfusion with
modified blood (i.e. antiTF antibody, anticDlS integtin antibody) following ischaemia/
reperfusion of 3tI hours has a beneficial effect on the "no-reflow" phenomenon compared to
reperfusion with unmodified blood in this model. However, the results of the present study
suggests that 3 hours of ischaemia followed by t hour of reperfusion with "unmodihed" blood
and 4 hours of ischaemia are likely to be periods of ischaemic injury resulting in irreversible
microvascular occlusions. The experiments conducted in chapter 3 involve the use of
"modified" blood.
These data also provide a baseline for future studies with agents which may ameliorate
microvascular occlusion without a period of repelfusion. However, one major deficit of this
(and most animal models of reperfusion injury) is the inability to accurately assess the degree
of neuronal injury and infarct size.
The possible effect of ischaemia/ reperfusion on vessel size has in part been addressed by the
addition of sodium nitroprusside to the perfusate at the conclusion of each experiment. In
each vessel group range from 4 to 50 pm, the percentage reflow t'emains relatively constant,
suggesting marked vasodilatation or vasoconstriction does not occul'. Galcia et al, suggested
in 1983 that capillary expansion and rupture occur in zones of brain ischaemia and
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Table 2.5
SLIDE NUMB NUMBER OF VESSELS PER VESSEL SIZE um)
4.0-7.5 7.5-30 30-50 0100 i > 100 Total
#202








MBG O2O7 394.00 23.OO 7.OO
s.ô0
0.00 1042.OO
NMBG 021 O 7s5.00 572.OO
443.OO
13.00 0.00 1343.00











NMBG O219 I oo 0.oo 1413.00
Ðta' 3?25,ffiû 178.0ü Ã"+ J {}.utJ 8286.CIû
nimal#207
NMBG O7O1 1615.00 16.00 4.00 1 oo 3035.00
NMBG O7O4 1907.00 31.00 6.00 1 00 3093.00
NMBG O7O7 1876.00 29.00 4.00 0.00 3179.00




NMBG 0713 1302.00 1783.00 26.00 6.00 0
0
31 17.00
NMBG 071 6 1376.00 1461.00 30.00 3.00 2870.00
NMBG 071 9 1281.00 1634.00 36.00 4.00 0
öL
00 2955.00
otat taz+.00 1 1859.$ü 1ü5.ûC) 37"tiO TJU 21167.fX)
Animal #176
NMBG 7601 681.00 406.00 30.00 15.00 1.00
0.00
11 3.00
NMBG 7605 s69.00 3s9.00 17.00 8.00 9s3.00
NMBG 7608 604.00 4?_4.OO
351.00
24.OO 9.00 1.00
NMBG 761 1 537.00 18.00 7.OO 0.00
0.00NMBG 76 4 439.00 31 8.00 20.00 6.00 i 783.00












SLIDE NUMBER OF VESSELS PER VESSEL SIZE
4.O-7.5 7.5 -30 >1 00 Total
nimal#2OZ
rsBG 0201 37s.OO 4.00 689.00
622.OOrsBG 0204 300.00 25.00 1 1.00 2.OO
rsBG 0208 374.OO 314.00 00 14.00 ?.oo 7?9.OO
rsBG 021 1 297.OO 3?7.OO 15.00 8.00 4.O0 6s1.00







rsBG 021 7 324.O0
298.00
324.OO 23.00
rsBG 0220 281.00 27.OO 9.00
78"0t
3.00




1833.00 34.00 6.O0 0.00 2830.00
07o4 1700.00 26.00 2.OO 0.00 2760.OO
0 07 909.00 1881.00 40.00 s.00 1.00 2836.00
SBG 071 O 898.00 1955.00 29.00 8.00 0.00 2890.00
rsBG 0713 895.00 168s.00 31.00 8.00 1.00 2620.OO





071 9 1515.00 18.00 2562.00
I 2236.0ü 208"t0 ¿å LUU 6"00 'tgI37.Ocl
#176
7601 268.00 147.00 10.00 s.00 0.00 430.00






rsBG 7607 2 43.00 15.00 421.OO
4s9.OOrsBG 7611
lsBG 7614




rsBG 7617 256.00 1 144
2?1.0O i 143
oo 0.00 430.00
rsBG 7620 00 18.00 1.O0 386.00




Percentage reflow for 3 hours ischaemia/l hour reperfusion and 4 hours
ischaemia/no reperfusion for each microvascular size








































































Summary of percentage reflow for each animal at each vessel size -













Summary of percentage reflow for each animal at each vessel size -









































Comparison of percentage reflow at each vessel size '
3 hour ischaemia/l hour reperfusion versus 4 hour ischaemia/no
reperfusion
P=0.476 p=0.311 p=0.s90 p=0.57+ p=0.660
4.0-7.5 7.5-30.0 30.0-50.0 50.0-100.0 > 100.0
microvascular size category (¡rm)
0
I MCA:O/R ! ucn:o
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Chapter Three
The effect on the "no-reflow" phenomenon of integrin uIIbB3 blocking
peptide (TP9201) in focal cerebral ischaemia
3.1 Aims
The TP9201 experiments were undertaken to address several questions. The pharmacokinetic
and pharmacodynamic studies were undertaken to determine whethel the drug was able to be
delivered to primates without adverse side effects; to study the pharmacokinetic properties of
the drug in primates; and the effect of the drug on template bleeding time.
The experiments in which TW20I was infused in subjects sustaining focal cerebral ischaemia
and reperfusion were undertaken to assess whether this RGD-peptide could modify the "no-
reflow" phenomenon. This effect would be mediated by the peptide inhibiting platelet
aggregation and hence microvascular occlusions, as discussed in Chapter 1.
3.2 Null Hypotheses
1. The novel RGD peptide TP9201 has no effect on platelet aggregation in primates.
2. TP9201 does not affect microvascular patency duling reperfusion following focal
cerebral ischaemia in primates.
3.3 Background
Synthetic RGD (Arg, Gly, Asp) -containing peptides can inhibit fiblinogen binding to ctIIbB3
and thus potentially have a useful antithrombotic effect (Plow et al, 1985). The ideal anti-
platelet peptide should have the following features:
1. Sufficiently potent for a reasonable dose regime
2. Dose-dependent efficacy
3. Limited bleeding time prolongation at therapeutic doses
4. Short serum half-life
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5. No effect on blood pressure, no immune lesponse or anaemia,
granulocytopaenia or thrombocytopaenia.
The inhibitory effect of these peptides is calcium-dependent to varying degrees and some of
them show increased activity by mole than lO-fold in low calcium (Plow et al, 1985; Barker
et al, 1992).
A recently-developed synthetic peptide G4120 has been shown to inhibit fibrinogen binding
to cr,Ilb p3 (Imura et aL, 1992). However, the effective intlavenous dose required for in vivo
inhibition of thrombus formation and ex vivo platelet aggregation results in a marked
prolongation of bleeding time, suggesting that this peptide may have a therapeutic effect with
a concomitant risk of haemorrhagic events.
The crllb p3 inhibitor used in the present study, TP92(ll, is a cyclic RGD-containing peptide
(acetyl-L-cysteinyl-L-asparaginyl-L-plopyl-L-arginyl-glycl-L-cr-aspaltyl-o-methyl-L-
tyrosyl-L-arginyl-L-cysteine-amide, cyclic I to 9-sulphide) which was supplied by Telios
Pharmaceuticals, Inc (San Diego, California). This has been found to inhibit ex vivo platelet
aggregation at doses which were not associated with significant prolongation of template
bleeding time (Tschopp et al,I992a).
This agent has been studied in the prevention of rethrombosis after thrombolytic therapy for
coronary artery occlusion in dogs in which mean lysis time and total dose of tPA was
significantly reduced and long term vessel patency was increased (Tschopp et al, 1992b). A
further study demonstrated reduction of platelet deposition on Dacron@ vascular grafts in
baboons without significantly incleased risk of bleeding (Faliakou et al,1992).
These in vitro and in vivo results support the effect of TP9201 on inhibiting platelet-platelet
interaction and possibly platelet-polymorphonuclear leukocyte interaction. Thus TP9201
may be a beneficial adjuvant agent in cerebral reperfusion by reducing microvascular
occlusions, as previous work in this laboratory has shown the presence of platelet aggregation
in the microvessels probably within I hour and certainly within 4 houls of reperfusion
contributing to "no reflow" phenomenon (Okada et al, 1994). Dilect platelet-endothelial
adhesion has not been documented in this model but this intetaction cannot be excluded.
In a recent study of the time-course of platelet and leukocyte infiltration in a rat model of
cerebral infarction, Garcia et al (1994) found that platelet aggregates were found mainly in
the arterial microcirculation and that this occurred most frequently after 12 hours of
55
ischaemia. Platelets were only found to occlude I.6 Vo of microvessels at 12 hours and 5.0Vo
at 48 hours. V/hilst reperfusion was not pelformed in this study, the low number of
occlusions caused by platelets and the late onset of platelet deposition, suggest that the
temporal paradigm used in the current TP9201 study (3 hours of ischaemia I I hour of
reperfusion) may be too brief to demonstrate a significant benefit in microvascular patency.
3.4 Materials and Methods
3.4.1 Preliminary Pharmacokinetic and Pharmacodynamic S tudies
Initial pharmaco-kinetic and pharmacodynamic studies were undertaken to determine the
optimal dosage of TP9201 to be infused during the focal cerebral ischaemia experiments.
A dose-response study in the 4 baboons was undertaken prior to the celebral ischaemia/
reperfusion experiments in the same animals. A schematic rcprcsentation of the experiments
conducted is shown in figure 3.1. The awake animals were chaired and 20 mls of blood was
drawn (10mls in lml citrate and l0mls in lml heparin) prior to bolus injection of TP9201 . A
template bleeding time was also performed. A bolus of 500 pglkg of TP9201 was then given
and this was followed by an infusion of 12 ¡tglkg /minute for a period of 4 hours. Six mls of
blood were taken and stored in heparin rt 1,2 and 3 hours and 2mls of blood taken and stored
in heparin at 4 hours 10 minutes (10 minutes after completion of infusion), 4 hours 30
minutes and 5 hours 30 minutes. Template bleeding times were pelfotmed at baseline, t hour
and 3 hours of infusion.
A full blood count, prothrombin time and activated partial thromboplastin time (APTT) were
performed on each blood specimen.
TP9201 plasma concentration was measured by HPLC (high performance liquid
chromatography) to determine the peptide pharmacokinetics. ADP and collagen-induced
platelet aggregation was used to assess TP9201 pharmacodynamics.
Platelet aggregation inhibitory concentrations (IC56 value) in citrated and heparinised plasma
were performed at each blood sampling.
Platelet aggregation was performed by spectrophotometric methods using a four-channel
aggregometer (Bio Data - PAP-4, Biodata Corporation, Hatboro, PA) which records the
56
increase in light transmission through a stirled suspension of protein - rich plasma (PRP) at
37o. Aggregation was induced with ADP (30ttM) and collagen (l0¡rg/ml) and values

































3.4.2 "Saline control" study
This study involved 2 of the previously studied subjects (#236, #237) to clarify the cause of
leukocytosis found during the TP9201 infusion study. They underwent chairing, baseline
template bleeding times and full blood count, and were then given a bolus of saline followed
by a 4 hour saline infusion of identical volume as given with the TP9201 infusion study. Full
blood counts were taken at identical times to the TP9201 study group.
3.4.3 Focal cerebral ischaemia / reperfusion experiment
Following the TP9201 study, an optimal dose of TP9201 for the focal cerebral
ischaemia/reperfusion experiment was calculated by the Telios scientists at a bolus of 675
pglkg and an infusion rate of 12 ¡t"glkglminute.
The experimental paradigm followed the previously desclibed MCA occlusion protocol, with
placement of the MCA occluding device 7 days prior to the actual experiment.
One of the 4 animals sustained a neurological deficit (N=85/100) during the implantation
procedure, but was deemed suitable to continue the experiment. The other 3 animals made an
uneventful recovery from the implantation procedure.
A diagrammatic representation of the experiment is shown in Figure 3.2. The chaired
subjects underwent baseline template bleeding times and drawing of blood for full blood
counts and platelet aggrega.tion studies. The bolus of TP9201 was given intravenously and
the infusion commenced. The injectable end of the MCA occluding device was exposed on
the scalp by a small incision under local anaesthesia and occlusion was performed with 100-
150 pl of fluid into the device.
Following this, all animals sustained a neurological deficit consistent with focal cerebral
ischaemia. Neurological scores were measured hourly and blood samples were taken hourly
for full blood count and platelet aggregation studies. Bleeding times were measured again at
1 and 3 hours. The infusion was continued until the experiment ended at 4 hours when the
subject underwent general anaesthesia and perfusion fixation of the brain with india ink in 47o
paraformaldehyde as previously described. No technical problems were encountered during
these experiments.
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The brain was then removed and underwent a period of 7 days fixation in AFA solution (877o
ethanol, I\Vo of 4Vo formaldehyde and 37o glacial acetic acid), prior to coronal sectioning at 5
mm intervals.
Visual inspection of the brain was undertaken for macroscopic evidence of decreased
perfusion and evidence of haemorrhage. Photographs of coronal sections were taken and
diagrammatic representations made. Blocks were then cut of identical sites of both basal
ganglia and temporal cortex. The left side (not ischaemic) served as a control. Twenty
consecutive sections were cut at 10 pm thickness by Hector Herreira (Department of
Cytology, Sharp Hospital, San Diego, California) and stained with basic fuschin/methylene
blue.
Blocks were cut from the central basal ganglia, or when haemorrhage was present, from an
area of basal ganglia adjacent to the haemorrhage and the identical region on the left side.
The details of the video-imaging system used to measure the number of patent vessels has
been given in chapter 2. Twenty sections from the right and twenty from the left basal
ganglia were cut and mounted. Each section was approximately 12 x 12 mm in size and 10
pm thick. The imaging system counts 90 fields per section (approximately 5x5 mm). Every
third slide is measured (if suitable) at an identical site to ensure that grey matter is measured










































3.5.1 Results of pharmacokinetic and pharmacodynamic study.
Baseline and peri-procedural characteristics of the animals are summalised in Table 3.1.
The subjects suffered no adverse events during this study.
(a) Haematological data:
Basic haematological data are summarised in Table 3.1.
Haemoglobin and haematocrits remained stable throughout the 5hr 30min study period.
Baseline haemoglobins were 10.9, 12.8, 13.4, and 13.5 gm/dl (mean 12.7). Platelet counts
also remained stable . Baseline values were 215 000, 210 000, 315 000 and 356 000 per pL
(mean 290 000 ).
Baseline white cell counts were 6 400, 9 100, 10 500, and 12 700 per LtL (mean 9 700). A
marked elevation of white cell count was noticed at2 hours (21 300,28 300, 33 000, 34 100 -
mean 30 700) which persisted during the 5hour 3Ominute study pedod in all animals.
Baseline template bleeding times were 2'30", 2'30",3'30" and 4 minutes (mean 3'15") in the 4
study animals. Bleeding times were then measured at 2 and 4 hours. In 3 of 4 animals a
further bleeding time was performed at 5 hours 30 minutes (i.e. 90 minutes after cessation of
TP9201 infusion. An elevation of bleeding times at 2 hours (5'45", 8', 11', 12'30" - mean 9
minutes 20 seconds) and 4 hours (10'30" , 12' , 12'45" , and 15'- mean 12'20") were noted.
Ninety minutes after cessation of infusion the bleeding times wete 7'15", 8'45", and 9'30" -
mean 8 minutes 30 seconds.
(b) Plasma levels of TP9201:
Plasma levels of TP9201 are given in Table 3.2.
Mean plasma levels of TP9201 were 0 at baseline,2.2 ¡tglml at t hour, 2.75 ¡t"glml at 2 hours,
2.6 ¡tglml at 3 hours and 2.55 pg/ml at the end of infusion. A rapid decay of plasma TP9201
was noted after cessation of the infusion,with a mean level of O.8pg/ml 90 minutes after
cessation of the infusion. A rapid response of ex-vivo platelet aggr:egation to this peptide was
noted (Table 3.3), both with collagen-heparin and with ADP-heparin.
The IC50 in citrate for the 4 animals was 0.10 t 0.03 pM and in heparin was 1.67 + 0.22 WINÍ.
The ratio of heparin / citrate of 17.39 was consistent with plevious expedence in the baboon
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dacron fistula model and appears to be due to the changes in calcium concentration rather
than the presence of anticoagulant .
3.5.2 Results of "saline control" study
The results of the "saline control" study are summarised in Table 3.4.
Baseline bleeding times were marginally higher than in the TP9201 study (4 and 6 minutes)
but were unchanged during the study period.
White cell counts were initially 14,100 and 18,600 per pL (mean 16,400). At 2 hours, the
values were elevated to 29.9 and 31.2 (mean 30.6). The leukocytosis persisted during the
study period at a slightly lower level, confirming this phenomenon to be a stress reaction
rather than an effect of TP9201.
3.5.3 Results of focal cerebral ischaemia / reperfusion with TP920l infusion
The clinical data and macroscopic tindings are summarised in Table 3.5. (The parameters for
the subjects not infused with TP9201 are given inTable 2.2)
(1) Haematological data
Subject haemoglobins and platelet counts were stable throughout the experiments. White cell
counts were elevated in a similar fashion to that noted previously, commencing at a mean of
l1 900, becoming elevated at t hour to 24 500 and at 2 hours to 30 800.
In the previously studied 4 MCAO/R animals, mean baseline white cell count was 11 000, at
t hour of ischaemia was 22 500 and at 3 hours was 25 400.
Similarly, bleeding times became elevated from a mean baseline of 3 minutes to a t hour
mean of 10 minutes 30 seconds and a 3 hour mean of 10 minutes 30 seconds.
(2) Neurological data
Within 5 minutes of MCA occlusion, a sustained leduction in neurological scores was noted
in all subjects in both cohorts. In the TP9201 study group, the scores werc 27 ,27, 46 and 50
(mean 37.5) and for the previously-studied group subjected to 3 hours ischaemia and t hour
of reperfusion, the scores were 27, 46, 47 and 76 (mean 49.0). These deficits persisted
throughout the four hour study period.
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(3) Macroscopic findings
Examination of the previously studied MCA:O/R subject brains demonstrated one specimen
with a small petechial haemorrhage only. Right basal ganglia pallor consistent with
ischaemia was noted in the brain of each animal. In the TP9201 group, a single animal
(#236) sustained right basal ganglia pallor. The remaining 3 animals sustained haemorrhage
of varying degrees into the ischaemic basal ganglia (see photographs in Appendix2). One
animal was clearly noted to have midline shift as a consequence of this major haemorrhage.
(4) Microvascular patency
Tables 3.7 and 3.8 detail the number of patent vessels (manifested by those containing carbon
tracer) for each given microvascular size in each section. The microvessels of 4.0 to 7.5 pm
diameter represent capillaries, 7.5 to 30 pm post-capillary venules and precapillary arterioles,
those 30-50 pm, small arterioles and venules, and 50-100 ¡rm large arterioles and venules.
The percentage reflow for each microvascular size grouping was calculated for each animal
by calculating the total number of vessels counted on 5 or 7 sections for given vessel size in
that animal on the ischaemic (right) side, divided by the total number of vessels counted on
identical number of sections for given vessel size in the same animal on left side, expressecl as
a percentage.
3 hour ischaemia / t hour reperfusion cohort (without TP9201)
This cohort also formed the control group in the 4-hour ischaemia study. The results are
detailed in Chapter 2, and the microvascular patency data arc given in Tables 2.3 and2.4.
3 hour ischaemia / t hour reperfusion cohort (with TP9201)
Percentage reflow data is given in Table 3.9.
Animal #236, which did not sustain an intracerebral bleed, had a mean leflow of 66.67o in the
4-7 .5 ¡tm range and 57 .07o in the 7.5-30 pm range. In the larger vessel groups, a 51.07o and
47.77o reflow was noted in the 30-50 pm and 50-100 pm range respectively.
The 3 animals sustaining haemorrhage in the basal ganglia had a mean reflow of I30Vo
(I497o, 1287o, ll2Vo) in the 4 to 1.5 pm range, l58%o, (l78Vo, I48Vo, 1487o) in the 7.5 to 30
pm range, 1237o (I36Vo,1057¡',1297o) in the 30-50 p"m range and 2.0 in the >50 pm range.
Overall reflow in each vessel group, compared to the subjects not infused with TP9201 was
Il47o compared to 46Vo (for 4-7.5 pm diameter vessels) (p< 0.01), l32Vo compared to 457o
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(7.5-30 pm) (p< 0.01), and 1057o compared to 767o (30-50 pm) (p< 0.05), see Figure 3.3..
These were all significant results using a 2 talled t-test.
3.6 Discussion
The preliminary pharmacokinetic and pharmacodynamic studies confilmed that the novel
cyclic RGD peptide, TP9201, could be given safely to baboons with no obvious side effects.
Considerable important data was obtained regarding the pharmacokinetics and
pharmacodynamics of this agent in an awake primate model.
The two findings of note were firstly, the white count elevation, which has been noted in
previous experiments as a "normal" stress reaction to chairing of these animals (del Zoppo et
al, 1991). On the basis of the finding of leukocyte elevation during the infusion period, and
the potential effect of TP9201 on platelet-PMN interactions, a "saline" control study was
performed on 2 of these subjects to assess white cell r'esponse to chairing for an identical
period of time. The "saline control" study confirmed that the leukocytosis observed during
the experiments whilst the animals were chaired was in fact a stress leaction rather than a
drug effect.
Secondly, the elevation of bleeding time from a mean of 3 minutes 15 seconds at baseline to 9
minutes 20 seconds at 2 hours; and 12 minutes 20 seconds at 4 hours, was surprising in view
of previous experiments utilising this agent, in which no significant elevation in bleeding
times were noted (Faliakou, 1992;Tschopp, lggzb). This suggests that the dose used was at
the upper end of the therapeutic window - i.e. range between anti-aggregatory effect and
elevation of bleeding time, which is evidently broader for this agent than other RGD peptides
cufrently under study.
The subsequent experiments undertaken involved the use of TP9201 in this focal cerebral
ischaemia/ reperfusion model. The most significant macroscopic finding in this study was the
presence of major intracerebral haemorrhages into the ischaemic basal ganglia in 3 of the 4
subjects. This finding may have several contributory causes. The high perfusion pressure of
brain fixative (160-200 mmHg) may be contributary, however the incidence of bleeding has
been higher in this study than in previous studies using identical conditions in this model.
The high levels of platelet inhibition and elevation of bleeding times resulting from the
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TP9201 infusion suggest that the drug may have been given at levels beyond its therapeutic
range. This RGD peptide has been shown not to intelact with extracellular matrix proteins
such as fibronectin and vitronectin (J Tschopp, M Pierschbacher, personal communication).
Nonetheless, the presence of ischaemic endothelium and exposed extracellular matrix would
presumably predispose to haemorrhage when the function of platelets is so effectively
blocked. Continuing work in this laboratory (Hamann et al, 1994, unpublished) has found a
decrease in the presence of the basal lamina after periods of reperfusion, which may
predispose to haemorrhagic events.
The microvascular patency results from this study are also difficult to interpret. The one
animal (#236) which did not sustain an intracerebral haemonhage was found to have a higher
percentage reflow than the control group. In the other 3 animals, and hence the group overall,
the percentage reflow in each vessel size for the TP920l-treated animals was greater in the
reperfused basal ganglia than in the control basal ganglia. The explanation for this is unclear.
Garcia et al (1983) reported early hyperreperfusion of ischaemic brain after 2 hours of
occlusion with increased diameter of vessels measured. This persistent post-occlusive
hyperaemia may contribute to the expansion and then rupture of microvessels when the
duration of ischaemia results in ireversible endothelial damage.
The role of artefact in the patency of vessels in the brain adjacent to haemorrhage is likely to
be important. One specimen (#234) clearly had sustained midline shift, and the mass effect of
the adjacent haemorrhage would be expected to adversely affect local haemodynamics,
possibly compressing microvessels in adjacent and contralateral brain tissue.
The options for future study of this agent are two-fold. The agent could be excluded from
further use in this model, or a further study could be conducted using a lower dose of TP920l.
A further pharmacokinetic and pharmacodynamic study should be performed to assess the
effect of the lower dose on platelet function (partly deducible fi'orn the washout data of the
present study) and bleeding time. A lower dose which was deemed suitable could then be
used to repeat the study.
A study performed concurrently from this laboratory demonstrated that intravascular fibrin
"accumulates in a time-dependent manner during focal cerebral ischaemia/reperfusion"
(Okada et al, 1994). Intravascular fiblin formation results fi'om the intetaction of platelets
with leukocytes, and platelet activation. Tissue factol also interacts with fibrinogen to
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generats intravascular fibrin. This study showed that although intravascular fibrin was
present at all periods of reperfusion (1, 4 and 24 hours) following ischaemia of 2 or 3 hours
duration, this accumulation of fibrin was only statistically significant at 24 hours of
reperfusion. Thus, the current paradigm of 3 hours ischaemia / I hour reperfusion may not be
ideal . Rather, a paradigm of 2 hours ischaemia I 8-24 hours reperfusion performed in
TP920l-treated subjects and untreated subjects would be more likely to clarify the role of
platelet deposition in microvascular occlusions. In addition, the group not treated with
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Pharmacology of TP9201 :
Ex vivo platelet aggregation in Heparin
(a) Aggregation with collagen (percentage)
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The aims of the in-situ hybridisation experiments were:
(1) to develop the skills required to perform this technique on brain tissues.
(2) to assess the suitability of using blocks of archived tissue (plasmalyte perfused and
stored at -70'C) from animals which had sustained varying periods of ischaemia and
reperfusion for in- situ hybridisation.
(3) to study the effects of ischaemia and repelfusion on mRNA expression of Tissue
factor (TF) and tissue-type plasminogen activator (tPA) in blain subjected to focal ischaemia
and reperfusion.
4.2 Null Hypothesis
The null hypothesis of these experiments is that focal cerebral ischaemia and reperfusion has
no effect on endothelial expression of TF and tPA mRNA, and hence that the cerebral
endothelium does not modulate the coagulation system during ischaemia/ reperfusion.
4.3 Background
4.3.1 Endothelial modulation of coagulation during ischaemia and reperfusion
A detailed discussion of this subject is given in Chapter I and will be briefly summarised
here.
Vascular endothelium is an anticoagulant and antithrombotic sutface. In response to a variety
of stimuli, including inflammation and ischaemia, vascular endothelium in cell culture can
become procoagulant. Endothelium is capable of generating thtombin, however on "resting"
or unactivated endothelium, thrombin is inactivated by antithrombin III or bound by
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thrombomodulin. Cytokine and other inflammatory mediators released during hypoxia down-
regulate thrombomodulin and up-regulate tissue factor (TF) expression.
Tissue Factor is extensively distributed in the adventia and media of cerebral non-capillary
microvessels (del Zoppo et al, 1992). Experiments using a TF-antibody supported the
concept that microvascular thrombosis occurs as a result of exposure of blood to sub-
endothelial TF in situations of increased endothelial permeability, such as VR (Thomas et al,
1993). The distribution of TF in the adventitia and media of cerebral vessels, and in
astrocytes in the cortex and Bergmann glial cells in the cerebellum suggest that TF forms a
"haemostatic envelope" around cerebral vessels, which can activate coagulation when
vascular integrity is disrupted (Drake et al, 1989).
In endothelial cell culture, cytokines IL-1 (Nawroth et al, 1986; Bevilacqua et al, 1986), TNF
(Nawroth and Stern, 1985; Bevilacqua et al, 1986) and LPS (Colucci et al, 1983) have been
shown to up-regulate TF activity. Bevilacqua et al, 1986, also demonstrated an additive
effect of two cytokines (TI'IF and IL-1) on TF activity.
Endothelial cells in vivo have not been shown to express TF under resting conditions or
following stimulation with LPS, suggesting different behaviour in vivo than in cell culture
(Mackman et al, 1993).
Currently no data are available in vivo regalding regulation of TF mRNA expression during
VR or other cerebral pathological processes, or whethel adventitial TF is exposed to
circulation clotting factors during VR secondary to increased vascular permeability.
Tissue-type Plasminogen Activator (tPA) is released continuously and in response to stimuli
by vascular endothelium. Gordon et al (1989), demonstrated tPA mRNA in endothelial cells
of small venules and the adventitia of larger vessels in primate tissues. The acute release of
tPA in response to stimuli such as ischaemia may occur via release of stored tPA or up-
regulation of tPA mRNA (Schneiderman et al, 1994). By utilising the techniques of in-situ
hybridisation, the role of tPA gene expression during VR should clalify the role of tPA in
modulation of the coagulation system during ischaemia and reperfusion.
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4.3.2 In-situ hybridisation background
In situ hybridisation involves the specific binding of a labelled nucleic acid probe to
complementary sequences in fixed tissue. The technique can be used to detect RNA, viral
DNA or DNA sequences on chromosomes. Initial work was done by Gall and Purdue in
1969 and since then DNA probes were used exclusively until 1990, when Troxler et al (1990)
first used a single-strand RNA probe, which has the advantages of greater sensitivity, higher
hybridisation efficiency and the absence of competing strands. Critical aspects of this
technique are that the target nucleic acid is retained in-situ, is not degraded by nucleases and
is accessible for hybridisation with the probe.
Utilising in-situ hybridisation techniques, mRNA activity of a particular protein can give
invaluable information in addition to previously available immunohistochemical techniques
which detect the amount of protein present. Thus gene expression in tissue sections in
reponse to stimuli can be detected in a semi-quantitative manner as well as localising
expression to a particular cell type. Complementary immunohistochemical studies localise
and semi-quantitate the expression of the actual protein. Northern blot analysis demonstrates
specific RNA expression in the tissue as a whole and furthel complements the other two
techniques.
4.4 Materials and Methods
The precise protocols used for the in-situ hybridisation experiments are based on those of
Biffo and Tolosano (1992), Wilkinson (1992) and Wilcox (1993) and are given in Appendix
3.
4.4.1 Probe preparation
Two types of single-stranded RNA probes can be used for in-situ hybridisation. Most
commonly, the DNA sequence of interest (or part thereof) is cloned into a plasmid vector so
that it is adjacent to 2 different RNA polymerase initiation sites at each end of the insert. This
allows the synthesis of a sense (negative control stland) and an antisense strand (probe) from
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the DNA template. The plasmid is linearised with a restriction enzyme which is selected in
such a way that plasmid sequences are not transcribed and the plobe synthesized with an
RNA polymerase. These probes are typically 250-1000 bases in length. Oligonucleotide
probes (20-50 bases in length) can be synthesised when the nucleotide sequence of a
particular DNA is known, and can be inserted into a plasmid. They are less sensitive than the
above probes but are relatively easy to generate using polymerase chain reaction (PCR)
techniques.
The optimal length of RNA probe is probably 400-800 bases, giving optimal specificity and
sensitivity. Short probes may give lower signals and high background. Probes longer than I
kilobase do not readily penetrate the tissue to bind to mRNA. (Probes can be shortened by
alkaline hydrolysis).
Labelling of probe
Probes can be labelled with radioactivity or haptens (e.g. biotin) which can be detected by
immunohistochemical techniques. Radioactive probes are generally believed to be more
sensitive than non-radioactive probes and are far more widely used at present despite the long
development times and safety precautions required.
In these experiments, probes were prepared by transcription using 35s-hbell"d UTP with a
specific activity of at least 1000 Cilmmol (Amersham). (Appendix 3.12).
Probe assessment
0.5p1 of probe was suspended in 10 mls of scintillation fluid and the scintillations counted on
a computerised scintillation counter. This value could be used to calculate percentage of
probe incorporation (the remainder being lost as unincorporated mucleotides). The other
0.5p1 of probe was run on a denaturing (RNA gel) to assess plobe length and suitability for
use in in-situ hybridisation. These gels were run with RNA matkers and stained with
ethidium bromide, which was usually inadequate for good visualisation. The gel was thus
dried in the speedvac between gladwrap and Whatman filter paper. The wafer-like gel was
then stored for 2-10 hours sandwiched against an X Ray plate at -70"C and then the plate
developed to assess probe length. Having confilmed a successful RNA transcription had
occurred, the probe was kept under ethanol at -70'C for up to 4 weeks.
Wilcox has recommended aliquotting desired amounts of the probe to be used over the next
1-2 weeks, to reduce the freeze-thaw cycles performed and hence probe deterioration.
81
4.4.2 Preparation of tissue for in-situ hybridisation
Tissues for in-situ hybridisation can be prepared for use by sectioning on a cryostat, after
embedding in plastic or wax, or tissues or embryos can be fixed and mounted whole.
Effective tissue fixation is essential for in-situ hybridisation and should:
(1) maintain good tissue morphology
(2) avoid degradation and loss ofnucleic acids from sections by endogenous nucleases
(3) allow adequate probe penetration (Troxler et al, 1990)
Unfortunately, the conditions for fixation are a compromise, as stronger fixation yields better
preservation of tissue mo¡phology but the increased cross-linking (from aldehydes) lowers the
accessibility of the target (Wilkinson, 1992). Fixation is generally performed at 0-4"C to
inhibit endogenous ribonucleases. The length of fixation depends upon tissue size: for
isolated cells, 20-30 minutes is sufficient, for tissues less than 1 cm thick, overnight is
sufficient, but for larger tissues (such as brain), perfusion with fixative may be necessary.
The major problem is that RNA stability is low in post-mortem tissues due to the presence of
stable, ubiquitous, active enzymes (RNAses) that specifically digest RNA molecules.
'Whichever technique of hxation is used, tissue RNAses must be rapidly inactivated. This can
be performed by
1. rapidly dissecting the tissues out of the animal and fi'eezing them
2. perfusion fixation of the animal by intracardiac injection
3. fixing small blocks of tissue by immersion in an appropriate fixative
Perfusion-fixation (e.g. with 47o paraformaldehyde or I7o glutaraldehyde) is generally
recognised as the best method for good presentation of tissue and cellular morphology and
optimal RNA retention, although this technique can only be used for laboratory animals under
general anaesthesia (Wilcox, 1993)
Freshly-frozen tissue gives good RNA integrity initially, however tissue morphology is not as
good. Tissues prepared in this way are usually vety small tissue blocks (less than 3x3 mm),
which are stored at -80oC, cut at the time of the experiment, mounted on poly-L-lysine slides
and immediately fixed with 47o paraformaldehyde (Wilkinson,1992). The tissues available
in our laboratory consist of primate brain (and arteries) which has been pressure-perfused
with plasmalyte, rapidly removed, sectioned into blocks of 1 cm x 1 cm x 0.2-0.5 cm and
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snap frozen in OCT at -70oC. These tissues are stored at -70oC and cut when required
(predominantly for immunohistochemistry) on a cryostat and mounted onto poly-L-lysine
slides. They are air dried (to fix to slides) and then fixed with 4Vo panformaldehyde for 30
minutes at 4oC. This technique gives good tissue prcservation for immunohistochemistry but
probably results in considerable RNA deterioration for in-situ hybridisation. Perfusion
fixation with plasmalyte followed by 4Vo paraformaldehyde and then following the above
procedure should give optimal results.
4.4.3 SlidePreparation
Slides must be treated ("subbed") to ensure that tissue sections or cells adhere throughout the
treatment and washes. The elimination of any exogenous RNAses must also be ensured.
Poly-L-lysine (S0¡rg/ml), is widely used and has been mainly utilised in this laboratory
(Appendix 3.14)
4.4.4 Prehybridisation
Prehybridisation forms the initial series of treatments in day 1 of the in-situ hybridisation
protocol, which is described in Appendix 3.15.
Following mounting the sections on "subbed" slides and treatment with 4Vo ptrafotmaldehyde
in phosphate-buffered saline (PBS), the tissues undelgo pretreatment, which is intended to
increase the efficiency of hybridisation and decrcase non-specific binding. Proteinase K (or a
pronase) digestion is used to increase RNA accessibility to the plobe. However, this step
results in some tissue architecture deterioration (particularly in tissues not fixed by aldehyde
perfusion) and thus the duration and concentration of ploteinase K used in this step must be
carefully titrated. Proteinase K treatment is followed by a refixation step to stop further tissue
digestion. Non-specific binding to positively-charged amino groups is prevented by
acetylation. Acetic anhydride in triethanolamine is used for this reaction.
Tissues are generally then dehydrated by progressively increasing concentrations of ethanol.
The hybridisation buffer (without probe) is usually added to the section (= 100 pVsection) and
incubated for I-2 hours.
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The IRNA and DNA caniers in the prehybridisation and hybridisation solution compete for
non-specific binding sites.
4.4.5 Hybridisation
For successful hybridisation to occur, incubation should be undertaken for 5-16 hours at =10-
15"C below the melting point of the hybrid. This temperature can be calculated, but usually
is =58-62"C.
The probe is melted at =80"C for 5 minutes and added to hybridisation buffer to give 5x105 -
1x106 counts per minute per section in = 100 pL buffer. Dextran is frequently added to the
hybridisation mixture as it has been shown to increase the kinetics of hybridisation by a factor
of five (Angerer et al, 1987), and the viscosity of the hybridisation mixture following addition
of dextran results in easier and more even application of probe to the section. Dextran in a
concentration of I07o was added in later experiments to the hybridisation buffer and a
coverslip is applied and the section incubated for 18 hours at 45-50 C, as the sections
deteriorated when incubated at higher temperatures in our laborator:y.
4.4.6 Post-hybridisation washes
Post-hybridisation washes are designed to remove probe which is non-specifically bound to
other RNA sequences. Stringency is the strength of conditions used for post hybridisation
washes. It is important to use appropriate stlingency conditions (formamide concentration,
temperature and salt concentration) to reduce non-specific and partially homologous binding.
The appropriaæ conditions are required to reduce background without compromising specific
binding. This can be achieved by washes of appropriate stringency, usually combined with
an RNAse treatment, which enzymatically digests non-hybridised molecules (if the
concentration of NaCl is greater than 0.3 Molar).
Dithiothreitol (DTT) is a reducing agent which eliminates the formation of disulfide bridges
between labelled 35S molecules (BiffoÆolosano, 1992).
Details of post-hybridisation washes used are given in Appendix 3.16.
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4.4.7 Visualisation of signal
The detection of the probe in the tissue sections depends upon whether a radio-labelled or
hapten-labelled probe has been utilised. For 35s-labelled probes, a signal can be observed by
placing the dried slides in an X Ray box overnight with a fast film sitting on them. This gives
useful information regarding presence of signal and specificity of activity (i.e. sense versus
antisense signal can be crudely compared). Following this, the slides are dipped in Kodak
NTB or Ilford #2 emulsion in a dark room at 45"C (Gowans, 1992). The dipped slides are
stored in a sealed box with a dessicator at -70oC and developed 2-8 weeks later (Appendix
3.17 and3.18).
4.4.8 RNAse free conditions
In-situ hybridisation requires ribonuclease-free conditions both for the preparation of
riboprobes and to prevent rapid RNA breakdown by ubiquitous RNAses.
Laboratory procedures undertaken to exclude IìNAses include:
(1) Glassware, plasticware etc.
Glassware should be rinsed with diethylpyrocarbonate water (DEPC water 0.I7o) and then
autoclaved, or baked at 180oC for 4 hours. Sterile one-use plastic ware is also suitable for
use. Equipment used for in-situ hybridisation should be kept separate from other laboratory
equipment.
(2) Hand contamination
RNAses on laboratory workers hands are a major potential source of RNAses, and thus clean
disposable gloves must be worn. For practical reasons, frequent glove changes are usually
required.
(3) Solution contamination
All solutions should be made with DEPC-treated millipore water (autoclaved). Molecular
biology-grade reagents are used.
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4.4.9 Controls for in-situ hybridisation
The use of appropriate controls is an important aspect of the ISH technique. The use of sense
and antisense probes are extensively-used controls. Messenger RNA is synthesized from
DNA in vivo in 3' to 5' direction thus producing a 'sense'mRNA plobe, which will not bind to
tissue RNA. An 'antisense'probe is complementary to the mRNA so that it will bind to the
tissue mRNA during hybridisation. Therefore the cDNA insert can be cloned in the 5'to 3'
direction, or transcribed from the opposite direction to the sense probe, as has been performed
during this study. This technique gives sense (negative control) and antisense probes of equal
length and G-C concentration, giving an excellent control for the ISH technique.
A further control is the use of a positive control, in which a palticular mRNA is known to be
abundantly expressed by a particular cell line. Recently, a cDNA insert of von Willebrand
Factor (vWF) has been obtained. vWF mRNA is strongly expressed on endothelial cells and
thus should give a positive signal on sections hybridised in parallel with the other probe under
study. A vWF oligoprobe has been successfully used in other studies (Wilcox et al, 1988) as
a positive control. mRNAs which are widely expressed in all or many cell types are not good
controls, as positive signals thloughout the tissue sections does not give any comparison
between positive and negative cells in sections.
Other controls include use of Northern blots to confirm the presence in the tissue under study
of the mRNA, and collocalisation of the ploteins and mRNA using ISH and
immunohistochemistry on serial or the same sections. The mRNA signal should be mostly
localised over the cytoplasm, although several published studies have accepted nuclear silver
grains as positive and quantitated them by counting (Simons et al, 1993).
Nuclear silver grains has been a problem in several expedments conducted, and may in part
be due to using excessive amounts of probe (> 1 x 106 counts/section rather than 3-5 x 105
counts/section). The decreased wash stringency used in these studies was probably also
contributary.
86
4.5 Results: In-situ hybridisation experiments undertaken
4.5.1 Attempts to perform ISH with fullJength TF and tPA probes
Full-length clones of human Tissue Factor (TF) cDNA were pJH9TF and pJH96. These were
the gift of JH Morrissey, PhD. Both clones had been inserted in plasmid pGE'lldTZi(+)
(Promega). The inserts were 1,805 base pairs in length and the plasmid was 3,000 base pairs.
E coli strain DH5cr had been transfotmed with the plasmid.
The tissue-type plasminogen activator (tPA) cDNA was the gift of EG Levin, PhD. The full
length tPA DNA contains 2530 base pairs, coding for a 562 amino acid polypeptide. The 35
amino acids preceding the mature sequence probably constitute a 20-23 amino acid signal
peptide followed by a hydrophilic "lead" sequence of 12-15 amino acids (Pennica et al, 1983).
The clone had been previously isolated from a cDNA libtary constructed in the plasmid
vector pBR322 from Bowes melanoma cell mRNA. This was digested with Bgl II, resulting
inaI974 base pair fragment, which encodes the tPA protein plus 200 base pairs of the 3'
untranslated end. The fragment was cloned into a BamH-1 site of the plasmid vector pBS
(Lævine et al, 1983). (However, when subcloning was performed in later experiments, the
sequencing suggested that the plasmid vector was in fact pBS KS+ with the tPA inserted at
the BamH-1 site.
Preparation of DNA templates
Transformed E coli was stored in 50Vo glycine at -70'C. Cells were picked up by a sterile
scraper and incubated in E coli growth medium containing ampicillin overnight in a shaking
incubator at3'7"C. Plasmid purification was performed using the Plornega Miniprep Kit, in
which = I.5-2 mls of medium is used for each preparation. The protocol is described under
"plasmid purification" in Appen dix 3.2.
Basically, the E coli bacteria are lysed and the plasmid DNA bound to the column resin,
which is washed and the plasmid DNA eluted into miclocentrifuge tubes at the end of the
procedure.
The total plasmid length is 3,000 (plasmid) and 197 4 (inselt) base pairs (in the case of tPA) or
3000 and 1805 base pairs (in TF). DNA is quite robust (particularly compared to RNA) and
was stored in water at -20"C.
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Prior to transcription, the plasmid DNA must be linearized adjacent to the insert, so that few
plasmid sequences are transcribed. Using 2 restriction enzymes which cut the plasmid
adjacent to each end of the insert allows the synthesis of a sense and antisense probe of very















The restriction enzymes were obtained from Promega and the protocol for DNA linearisation
obtained from Sambrook et uf. íf ggg) (Appendix 3.3). Following incubation for 90-120
minutes at37"C, a TAE or TBE gel (Appendix 3-7) was used to assess completeness of
digestion.
Advice was obtained from Pauline Lee, PhD, who recommeded the use of TBE gels. The
TBE or TAE gels are made with ethidium bromide, which intercalates between the DNA
bases and allows visualisation under UV light. After photographing the digested DNA
alongside DNA markers, which allow the DNA length to be assessed, the linearised DNA is
cut out of the agarose gel (only possible with TBE gels) and this small block of gel which
contains the desired DNA undergoes the gene-clean protocol (using finely ground glass,
"glass milk").
The other value of the DNA gel is that the concentration of DNA can be approximated by
comparison of the brightness of the linearised DNA band compared to the markers of known
DNA concentration.
Linearisation (digestion) appeared to be incomplete on many occasions for reasons that were
not clear, with DNA remaining apparently supercoiled when viewed on the gels.
Several enzymes cut the plasmid with a 3' overhang and thus should have the 3' end "blunted"
(or filled in) with addition of free nucleotides and Klenow polymerase. This enzyme was
added to the reaction mixture at the end of the linearisation reaction with dNTPs and
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incubating for 15 minutes at 30"C (linearisation protocol). The enzymes KPN-1 and Sac-1
required this treatment.
Probe preparation
Following extraction of linearised DNA and "gene-cleaning" as described above, the
concentration of DNA was measured by one of two techniques:
1. A small volume was run on a TBE gel with malkers, allowing visual assessment of
approximate DNA concentration.
2. Spectrophotometric analysis of DNA concentration.
Probe preparation was then undertaken, using the transcription protocol (Appendix 3.12).
Concentration of UTP in the final reaction mixture needs to be at least 10pM for good
transcription, however Biffo & Tolosano (L992) recommend increased UTP concentration (25
pM) for long probes. Thus, increase volumes of hot UTP must be used and dried down, or
"cold" (unlabelled) UTP added. "Cold" UTP was added on several occasions, but did not
seem to improve probe synthesis.
Following incubation of the reaction mixture, the DNA template was removed by DNAse
digestion, and the RNA was precipitated using phenol-chlotoform extraction with ethanol
wash. This technique removes unincorporated nucleotides.
Most attempts at RNA preparation were unsuccessful, with no pellet forming in association
with the tRNA carrier (seen as a white flocculent precipitate just above gtanular, darker tRNA
carrier). As expected, scintillation counts of the supposed RNA (several microlitres at the
bottom of the micropipette) were low, suggesting poor probe preparation.
On several occasions, higher counts were achieved, and an RNA gel dried and exposed to an
XR plaæ overnight suggested the synthesis of a series of incomplete transcripts.
Experiment using TF9 sense and antisense
Sections from animal#218 were used. [3 hour ischaemia/ t hour reperfusion, plasmalyte-
fixed frozen sections. Right (ischaemic) and left (normal) basal ganglia usedl
The in-situ protocol (Appendix 3.15) was used with = 600,000 counts per minute (cpm) per
section used. Approximately 75pl of prehybridisation buffet was added, however Dextran
was not added to the hybridisation buffer.
TF9+ (with cold nucleotides) was found to have 490,000 cpm/pl and thus
I.25¡tI of probe was used per section in 75pl buffer.
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TF9- was found to have 125,000 cpm/pl and thus
4pl was added per section.
This experiment was repeated using sections from the right and left basal ganglia of animal
#203.
A further ISH experiment was undertaken using brain and aortic sections from animal#218.
Problems with these experiments included poor tissue preservation and loss of tissue from
slides (see Materials and Methods) and minimal non-specific activity on autoradiography.
Later development of emulsion confirmed the lack of activity.
Modifications which appeared to be required to obtain a signal on well-preserved tissues were
two-fold:
l. Shorter probes were necessary. This could be achieved by synthesis of an
oligonucleotide DNA insert (30-50 base pairs) in the DNA core laboratoty of Scripps Clinic.
A more specific probe, which would be more suitable for mRNA which is not abundant
involved subcloning the DNA which was available to obtain pr:obes of between 300 and 1,000
base pairs (preferably 300-600 base pairs).
2. Larger specimens such as brain should probably be perfusion-fixed with an aldehyde,
such as 4Vo paraformaldehyde or glutaraldehyde. This was not undertaken for several months
due to animal constraints.
4.5.2 Subcloning of DNA to obtain suitable length DNA inserts for in-situ hybridisation
The technique of DNA subcloning involves:
1. obtaining the DNA sequence of the insert and plasmid
2. generating a restriction map, so that appropriate enzymatic digestion of the DNA can
be performed, which would excise the desired fragment and also be used on the new plasmid
so that the fragment could be inserted into the opened plasmid at an appropriate restriction
site.
3. the DNA insert must be ligated into the plasmid.
4. "competent" E coli cells must be made, so that the plasmid can be inserted and thus
replicated.
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5. colonies containing the desired plasmid must be selected, grown, Mini-prepped and
sequenced prior to use of the insert as a DNA templaæ for mRNA probe pl'eparation.
Sub-cloning of pJH96 - Human Tissue Factor cDNA
Human Tissue Factor (TF) is a263 amio acid glycoprotein. The pJH96 cDNA insert is 1.66
kilobase (kb) in length and had been cloned between the Sma-I and BamH-I sites on pGEM
7Zf(+) [Promega] . The vector is 2.98 kb in length.
The coding sequence is sited between bases 4-789 in the cDNA. A 3' non-coding sequence is
sited from bases 793-1623, followed by a partial poly-A tail.
The DNA sequence (supplied by JH Morrissey) was fed into the MAPSORT programme and
a restriction map obtained. An enzyme which would cut out a fragment of suitable size in the
coding region was sought.
Restriction eîzyme EcoR-I cuts the sequence at0,646,1641 and 1662 giving fragments of
646,995 and 2I base pairs. This 646 base pair fragment was felt to be suitable. (The EcoR-I
site was adjacent to the Sma I site.)
Preparation of DNA fragment for subcloning
Digestion of TF96 plasmid was thus undertaken with EcoR-I for 1.5 hours, run on a TBE gel
alongside DNA markers. Figure 4.1 (lane 5) shows the linearised bands of plasmid (2.98 kb),
and the 2 shorter TF fragments (995 and 646 base pairs) which ttavel further down the gel.
The 646 base pair fragment was excised under UV light and extracted using the "glass milk"
protocol (Appendix 3.4).
The plasmid pGEMTZf(+) was cut with EcoR-I, and this was also excised from a TBE gel
and gene cleaned.
The Tissue Factor insert and pGEM were combined in a molar ratio of approximately 3-5:1
insert:plasmid to facilitate plasmid insertion. The plasmid and insert werc heated to 65"C for
2 minutes, allowed to cool and T4 ligase added, which facilitates ligation of insert into
plasmid. This mixture was incubated overnighted at 16"C. E coli cell line JM109 were
supplied with the pGElr.dTZi(+). However, E coli cells NM522 and JM109 cells were made
competent using the transformation protocol.
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B acterial transformation
Bacterial transformation is a procedurc in which suitable strains of bacteria (E coli XLI Blue
for tPA and E coli NM522 fot TF) are "transformed" with circular plasmids of DNA
containing the desired insert between restriction sites and a sequence for antibiotic resistance.
The technique involves obtaining logarithmically growing cells, which are suspended in
calcium chloride on ice to generate "competent" cells, which ale briefly "heat-shocked" at
37"C to allow plasmid entry from the surrounding buffer. The cells are particularly fragile at
this stage.
When grown on an agar plate containing antibiotic (Ampicillin * tetracycline), only those
cells containing the plasmid (and hence DNA coding for antibiotic resistance) will grow.
Thus colonies which are present after incubation overnight contain the plasmid of interest.
Colonies can then be picked off and grown in bacterial growth medium for use or storage in
-70'C (with glycerol). The protocol details are given in "Transformation of bacteria",
Appendix 3.10) and based on the method described by Sambrook et al (1989).
Approximately 100ng of ligated plasmid containing TF646 DNA were added to 200 pl of
competent cells, incubated on ice for 30 minutes and then "heat-shocked" at 37"C for 5
minutes. lml of LB culture medium was added and the mixture incubated for 45 minutes at
37"C. The cells were then spread on plates (LB/Agar/Ampicillin) which had been coated
with Isopropyl thio-ß-galactoside (IPTG) and 5-blomo-4-chloro-3-indolyl-p-D-
galactopyranoside (XGal). IPTG and XGal were used to differentiate colonies in which the
plasmid had religated without the TF insert from those containing the insert. Colonies
containing the pGEMTZf(+) plasmid without alteration would remain blue, whereas
interruption of the sequence leads to a white colour of the colony.
As a negative control, 100p1 of transformed bacteria were spread on two plates. These would
not contain the plasmid, which also coded for antibiotic resistance and hence should not
grow.
Following this incubation, the colonies all appeared blue, suggesting religation of the plasmid
without the TF insert.
The most likely cause of this was that the molar ratio of insert:plasmid in the ligation reaction
was too low and thus the experiment was repeated, using a higher ratio of insert
DNA:plasmid (7.5:1).
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Several further attempts resulted in growth of blue colonies only. Following this TF DNA
was extracted with phenol-chloroform, and the ligation lepeated. Several pale colonies
resulted following this procedure. 14 colonies were picked off and grown up overnight.
Minipreps were performed the next day and cells also saved in glycerol at -70"C.
The plasmid DNA was cut with EcoR-I and run on a gel (thus excising the insert). All
colonies contained the insert. It appeared possible that a concentration problem with IPTG
and XGal may have impaired the contrast between blue and white colonies (on previous
attempts at growing colonies).
Sequencing of this DNA in the Core Laboratory of Scripps Clinic was unsuccessful. As a
result of this, lpl of plasmid DNA from one colony was reinserted into competent NM522
cells and grown on 4 plates overnight, to ensure a single colony growth. Several pale
colonies and one definitely white colony were picked off the next day, grown up and
miniprepped.
The TF insert was present in these colonies after digestion with EcoR-I, and thus the plasmid
DNA was sent for sequencing.
The plasmid was cut with EcoRI, Sac-I, ApaI and HindIII (Figures 4.I, 4.2 and 4.3).
Digestion with EcoRI resulted in cutting out the 646 bp fragment (seen in lane 2, figure 4.1;
lanes 1 and 2 in figure 4.2; and lane 2 in figure 4.3). However, when the plasmid was
linearised with Hind III (lane 4, figure 4.3) and Apa I (lane 3 figule 4.2, and lane 4 figure
4.1), plasmid of approximately 4.3 kb. length was obtained, as this band ran close to the
fourth band ot the lambda-Hindlll marker. (The marker bands are given in Appendix 3.6).
This suggested that a double insert of TF646 had been incorporated into the plasmid. This
was not initially appreciated. Following realisation of this situation, the restriction map was
reviewed to hnd an enzyme which would cut the insert within the 646 bp region. Hepa I was
one of the few enzymes which would do this. Thus the double insert could be cut and
religated, thus leaving a single TF646 insert in the plasmid.
Use of the enzyme Hepa I to cut the insert was unsuccessful on several occassions (lane 1,
figure 4.3). Ava I was then successfully used to cut the double insert and ligation was
performed overnight at 16'C. The ligation mix was then inserted into competent NM522
cells and plated. White colonies were seen and picked for growing up.
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At this stage, further discussion had taken place with JH Morrissey, who offered a sub-clone
for use.
A 780 base pair subclone (pJHzÐ was obtained. The cDNA was taken from the coding
region and cloned between the Bam H-I and EcoR-I site of pGEMTZf(+).
TF(pJH24) sense
antisense
This plasmid was successfully inserted into competent NM522 cells. White colonies were
picked and individually grown in growth media, Miniprepped and plasmid DNA extracted.
The DNA was sequenced successfully (see Appendix 5.1 and 5.2). Digestion and "cold"
transcription was successfully performed. Figure 4.4 shows the T7 band (lane 1) and SP6
bands (lane 3 and 4). T3 (lane 2) could evidently also be used for prepaling the sense strand.
The bright "blobs " at the lower end of each lane is the carder tRNA.
Subcloning of tPA cDNA
The tPA cDNA used was a1,974 base pair fragment cloned into a Bam H-I site on PBS
(Pennica et al, 1983). This sequence was entel'ed into the MAPPLOT programme and a
restriction map obtained. EcoR-I was found to cut the plasmid at 0, 804 and 1279, giving
fragments of 804, 47 5 and 3.8 kb (figure 4.5, lanes I -4 ). The 47 5 bp fragment was felt to be
the most suitable for use.
The tPA was digested with EcoR-I and the 475 and 804 bp fragments cut out and gene-
cleaned These two fragments were ligated into plasmid pBS, which was the gift of E. Levin
PhD. However, when sequencing was performed, the plasmid sequence was actually
consistent with plasmid pBSIIKS(+/-). EcoRI cuts this plasmid midway between T3 and T7
at plasmid base pair 707. The plasmid was then inserted into competent cells (as described
for TF96), which were plated out overnight.
White colonies were seen after overnight incubation. These white colonies were individually
picked off and grown up, a Miniprep \ryas performed on each colony (and 0.5 mls save stored







The plasmid DNA was then cut with EcoRI to confirm that the insert was cut out of 
"u"r?O
colony. The DNA was also linearised with HindIII and BamHI (separately). Suitable
plasmid DNA was then sent for sequencing using M13 and M13r transcriptase. The 804 bp
insert was successfully sequenced, however the desired 47 5 bp inseft was not.
A new batch of plasmid from whichthe 475 bp insert could be excised by digestion with
EcoRI was grown up and was successfully sequenced (see Appendix 5.1 and 5.2).
linearise with RNA polymerase
T7
T3BamHI
Preparation of "cold" RNA probes using cold rUTP was perfolmed . The nucleotide was not
dehydrated as was performed for "hot" transcription as the concentration of cold rUTP was
several-fold higher for cold transcription. The RNA was phenol-chlotophorm extracted, and
run on an Ethidium bromide-stained denaturing gel. Bands were seen at approximately
500bp length, consistent with full-length transcripts (figure 4.6 -Tl in lane 1, T3 in lanes 2
and 3, and figure 4.7, with T7 inlane2 and T3 in lane 1).
Radio-labelled probes were then prepared using the tPA475 bp DNA as a template. Good
incorporation was obtained as assessed on activity counts.
ttPA(+) 1.1x107, tPA(-) t.ZxL}7 )
Autoradiography of the dried RNA gels also demonstrated good RNA bands (Figure 4.8)
Later transcriptions showed much better results with T7 than T3, which may have contributed
to the high levels of non-specihc binding during ISH, since T3 gave the antisense probe.
Advice from colleagues confirmed that T7 was a superior polymerase to T7 or SP6.
4.5.3 Von Willebrand Factor as a Positive Control
The lack of strong positive signals obtained during early ISH experiments had made the
assessment of the cause of the problems difficult. Thus a probe which would give strong





V/illebrand Factor (vWF) probe for this purpose as strong signals are obtained with
endothelium.
J.Ware PhD works extensively with vWF and donated a 870 bp insert which was felt would
be suitable for use as a DNA template . This fragment coded for amino acids 44I-7 30 in the





or Sac-I with Klenow
vWF Antisense (-) KPN-I
The plasmid DNA was linearised and the insert cut out (figure 4.9 - lane 1 contained plasmid
and DNA linearisd with KPN-I; lane 3 plasmid linearised with BstX and lane 5 plasmid
linearised with Sac-1. The insert was cut out with KPN-l and Sac-l in lanes 2,4,6,'7,8 and the
870 base fragment is seen). A cold transcription was performed. This was then run on a
denaturing (RNA) gel and demonstrated a clear T-7 band, however only a weak T-3 band was
seen (figure 4.10). Radio-active probes were then synthesised using new T-3 polymerase.
Activity of vWF antisense probewas 8.8x106 cpm/ul and 6x106 for the sense, suggesting
reasonable incorporation.
4.5.4 In-situ hybridisation experiment using sub-cloned probes
Using animal number 217 (control cortex and aorta- 1 brain and 1 aortic section per slide).
TPA activity was thought to be potentially a good positive conttol, however Gordon et al,
1989, found very low levels of tPA mRNA in rhesus monkey aoltas, and the tPA activity seen
was actually in the adventitial venules adherent to the aorta.
Thus the addition of aortic sections was unlikely to produce useful levels of tPA activity to
act as a positive control.
This ISH experiment was performed with the tPA probe and several conditions were varied to





(l) Half of the slides were treated with poly-L-lysine and the remainder with "h.o*16
Alum preparation.
(2) Slides were treated with Proteinase K (20 pg/ml ) for either'7.5 minutes, as previously
used, or for 5 minutes, as the shorter incubation peliod was likely to improve tissue
preservation and architecture.
At this time, Dextran was not used in the Hybridisation buffer. 200 pL of prehybridisation
buffer was added, and the slides coverslipped overnight after addition of the probe.
Results : Autoradiography showed minimal activity associated with the sections.
Development of emulsion-coated slides after 23 days incubation showed poor retention of
brain tissue. The aortic sections were reasonably well-preserved. The aoftic sections showed
minimal non-specific activity.
ISH experiment undertaken using animal number 174 (control -no VR, plasmalyte fixed)
with 1 section of brain and 1 section of femoral aftery ol aorta pel slide.
tPA was used as the probe (Sense and antisense).
In order to try and improve brain tissue retention, Proteinase K was used for a shortel'
duration ( 5 or 7.5 minutes), and sections were cut 10 and 20 ¡tm thick to assess whether
thicker sections would demonstrate better tissue architecture.
Results: Tissue preservation was slightly impr:oved. Minimal signal was obtained in the
sections, most of which were exposed during autoladiography development.
ISH experiment with major pre-treatment modifications.
The previous ISH experiments had given sparse aortic signals, however the brain sections in
particular had been severely digested.
Options considered and used for the next experiment included
l. no Proteinase K treatment
2. A much lower concentration of Proteinase K (1pg/ml cf .20 pg/ml)
3. Saponin as a pretreatment, as this has been used with good tesults, allowing tissue
penetration by probes whilst maintaining good tissue architecture (Yamawaki et al, 1993).
Saponin O.IVo in PBS was used for a 20 minuæ incubation.
97
Dextran LÙVo was added to the hybridisation mix, as this has been shown to improve probe
penetration of tissue.
Brain and aorta from animal 174 werc used. Ten and 20 pm sections were used.
Results: Autoradiography and emulsion development showed no activity. However, all 3
pretreatment techniques demonstrated much improved tissue preseruation.
ISH experiment using paraformaldehyde-fixed brain.
Brain sections of animal 116 (several-year old paraformaldehyde-perfused specimen) were
used in addition to sections of animal 174.
The freshly-prepared tPA probes showed discrete bands on autoradiography of the RNA gel
and high counts on scintillaton counting, particulally the T-7 plobe (Sense probe), figure 4.8.
This experiment was repeated using brain and femoral artery sections from animal 245 (VR
of 3lI and paraformaldehyde perfused, although probably for an inadequate amount of time
due to pump problems during experiment). The second of these 2 ptocedures underwent
hybridisation with tPA and v'WF probes.
The post-hybridisation washes were varied , using the 2 plotocols of Biffo and Tolosano
(1992). One protocol reduces non-specific binding utilising high-stlingency washes, and the
other mainly by RNAse A treatment. This digests single stranded RNA, thus leaving only
RNA bound firmly to tissue mRNA.
Pretreatment was performed with Proteinase K (lpg/ml for 20 minutes) and 10 pm sections
were used.
Results: Tissue preservation was much better in the paraformaldehyde-fixed sections.
Minimal signal was seen on the RNAse -treated sections (upper half of figure 4.10).
However, the sections treated with high stringency washes showed strong signals on both
autoradiography and emulsion development. (lower half of figure 4.10).
The positive silver grains were mostly localised to the grcy matteL, and were clustered over
the nuclei. The intensity of the signals were indistinguishable in the sense and antisense
sections. These findings arc consistent with non-specific binding.
The possible causes of high levels of non-specific binding include:
(1) Excessive amounts of ptobe (e.g. if more than 106 counts used per section,which was
not the case in this experiment [5x105 "p- 
per section])
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(2) Contaminated DNA template (with both orientations present). This was considered
unlikely as both tPA and vWF hybridised tissues gave the same rcsults.
However, the decision was made to re-sequence both DNA inserts to exclude this possibility.
Sequencing excluded the possibility of contaminated DNA.
(3) The use of 5OVo formamide as a first post-hybridisation wash, and increasing the
number of posrhybridisation washes was also considered and adopted for use with half of the
sections for the next experiment.
However, the cause of the high level of non-specific binding remained difficult to explain.
In situ hybridisation using protocol modifications to reduce non-specifïc binding
This experiment was undertaken using sections fi'om anim als #245 and 233 (3 hour
ischaemia/1 hour reperfusion, adequately pefusion-fixed with 27o paraformaldehyde).
Control cortex and aorta were used. Probes used were tPA and vWF with 3x105 counts
added per section. Formamide (507o) was used as first post-hybridisation wash as a variation
of the standard protocol in half of the sections .
Results: Autoradiography demonstrated differences in signal intensity obtained for v'WF in
brain sections of animal233, suggesting that adequate tissue fixation had not been previously
achieved and that endogenous RNAses had contibuted to the difficulties encountered in
obtaining signals.
Further experiments were planned using sections fi'om animaIz33.
4.6 Discussion
In situ hybridisation is a powerful tool for studying gene mRNA expression in tissue sections.
The technique can localise and quantitate mRNA expression, particularly when used in
association with immunohistochemistry and, if desired, Northern blot analysis.
This technique involves a series of sophisticated molecular biological techniques as well as
meticulous care of tissue sections to prevent loss of the section from the slide, preserve tissue
architecture and prevent RNAse digestion of tissue RNA. Whilst the results obtained during
these pxperiments have not obtained definitive results to date, considerable development of
the relevant techniques has occumed.
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Following the initial failure of the technique with full-length probes (1.9 and 1.8 kilobases),
the technique of subcloning these inserts was acquired. Following sequencing of the
subcloned inserts, RNA probes were successfully prepared.
Tissue fixation and preparation was also a major problem during the ISH experiments.
The technique of ISH entails multiple washes at various temperatures and in particular a
proteinase-K digestion is performed to increase probe access to cellular RNA. These
procedures can readily result in loss of tissue from the slide. This was particularly a problem
using plasmalyte-perfused frozen sections. The slide preparation technique was modif,red on
several occasions to try and improve tissue adherence.
A more meticulous slide cleaning protocol was adoped, which entailed dipping in I7o IM
HCL in 707o ethanol for 30 minutes followed by dipping in di-ethyl pyrocarbonate (DEPC)
water for 30 minutes, followed by dipping in 95Vo ethanol for a further 30 minutes. The slide
racks were placed in an oven at 70"C until dty and then dipped in poly-L-lysine (in Tris) for
30 minutes and dried overnight. Following this, the slides were stored at 4"C with a
dessicator for up to 1 month. The use of proprietary-treated slides such as Superfrost Plus
was not used during this research period.
Proteinase-K digestion was initially undertaken at a concentration of 20¡t"glmI and incubated
for 10 minutes. However, as the brain tissue used was not parafolmaldehyde perfusion-fixed
for the majority of the study period, this enzyme resulted in considerable tissue digestion, loss
of architecture and tissue loss from the slides. Better results wele obtained using the lower
concentration of lpg/ml, however it is unclear whether this lower concentration would affect
probe binding adversely.
Saponin has been used to replace proteinase-K and has been reported to maintain good tissue
morphology whilst maintaining hybridisation sensitivity (Yamawaki et al, 1993). This was
employed during one ISH experiment.
Utilisation of paraformaldehyde perfused tissues resulted in much improved tissue retention
on slides and better tissue morphology during the later experiments.
The final series of experiments undertaken utilised adequate probes and well-fixed tissues.
The major problem encountered at this stage ìrvas non-specific binding of probe.
Modifications of technique, including increased stringency of post-hybridisation washes,
modification of proteinase K pre-treatment, variation in probe concentration (varying number
of counts per slide) and addition of folmamide in posrhybridisation washes were emplor.Ol00
The DNA inserts used for probe preparation were also re-sequenced to ensure that there was
no contamination with reversed inserts.
All of these modifications resulted in minimal improvement in non-specific binding, and thus
further input by scientists experienced in this technique appeared essential.
Once it has been successfully developed, this technique provides opportunities to study the
behaviour of a large number of relevant genes in this VR model. Thus sections of preserved
tissue can be probed for RNA expression of cytokines, stl€ss proteins, coagulation proteins
(such as tPA, PAI-1, TF) and cell adhesion molecules (e.g. ICAM-I, E-selectin). This
technique has enormous potential for providing information to understand the mechanisms
involved during reperfusion of ischaemic tissues and hence provide insight into possible
amelioration of reperfusion injury.
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Figure 4.1
Photograph of DNA gel (Tissue factor)
7
646 base pairs->
Lane2 and 3 = TF646 cut with EcoRI
Lane 4 = TF646 cut with ApaI and Sacl to rcmove insert (shows 1.3 kb insert)
Lane 5 = TF646 cut with EcoRI (giving 995 and 646 ba.sc pair fragments)












Photograph of DNA gel (Tissue Factor)
ta3 m
646 base pairs -->
Lanes I and 2 = TF646 cut with EcoRI








Photograph of DNA gel (Tissue Factor)
646 base pairs -+
Lane I = Plasmid containing TF646 digested with Hepal
Lane2 = Plasmid containing TF646 digested with EcoRI
Lane 3 = Plasmid undigested




Photograph of RNA gel
("cold" transcription of Tissue Factor Probe PJH24)
Lane 1 = T7 RNA polymerase
Lane2 = T3 RNA polymerase
Lane 3 = SP6 RNA polymerase
Lane 4 = SP6 RNA polymerase (dilterent batch)
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Figure 4.5
Photograph of DNA gel




Lanes 1-4 = tPA digestion with EcoRI shows 3 tiagments
(i) plasmid 3 kb
(ii) 804 bp fragment
(iii) 475 bp fragment
Lanes 5-9 = Plasmid PBS digestion (3 kb)
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Figure 4.6
Photograph of RNA gel
tPA "cold" transcription
Lane 1 - using T7 RNA polymerase
Lanes 2 ¡nd 3 = using T3 RNA polymerlse
r07
Figure 4.7
Photograph of RNA gel
tPA "cold" probe preparation
t,z-?-z--f 3
Lane 1= T7 (good band seen at approx. 500 bases)
Lane 2 = T3 (good band seen at approx. 500 bases)
(Carrier tRNA at lower ends of Lanes)
Marker not well visualised.
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Figure 4.8




Lane 1 = T7 ("sense" probe)
Lane 2 = T3 ("antisense" probe)
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Figure 4.9
Photograph of DNA gel
(vWF digestion)
==s-L== :tÞ--ii,it:t-!
, r - -F- - _
,:
z3+5-613,110¡'lv1
Lane I = Plasmid containing vWF linearised with KPN-I
Lane 3 = Plasmid containing vWF linearised with BstX
Lane 5 = Plasmid containing vWF linearised with SacI
Lanes 2,4,6,7 ,8 = vWF insert cut out with KPN-I and SacI
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Figure 4.10
Photograph of RNA gel
vWF "cold" transcription
Lane 1 - using T7 RNA polymerase (band seen)
Lane2 - using T3 RNA polymerase (band not seen)
Lane 3 - using T7 RNA polymerase (band seen)
Lane 4 - using T3 RNA polymerase (bancl not seen)
lll
Figure 4.1 I








Reperfusion injury is a complex pathophysiological process, which involves a large number
of major aetiological factors. These factors have been thoroughly discussed in Chapter 1.
The experiments described in this thesis have addressed two major aspects of reperfusion
injury following focal cerebral ischaemia. These are the "no-reflow" phenomenon and
endothelial modulation of the coagulation system during ischaemia and reperfusion.
The "no-reflow" phenomenon has been extensively studied in this laboratory using a video-
imaging system which accurately measures the number and size of microvessels patent in
brain sections. The standard paradigm has been 3 houts of ischaemia followed by t hour of
reperfusion, and this event has been associated with a 30-50Vo patency of microvessels 4-50
pm in diameter. Previous studies have demonstrated significantly improved patency by
infusing a þ-2 integrin blocking antibody (to reduce leukocyte adhesion) and an anti-Tissue
factor (TF) antibody (Mori et al, 1992; Thomas et al, 1993), confirming the role of leukocyte
adhesion and coagulation system activation by exposure of blood elements to adventitial TF
in the "no-reflow" phenomenon.
The first two projects undertaken to clarify the "no-reflovr" phenomenon further involved a
comparison of microvascular patency following 4 hours of middle cerebral artery (MCA)
occlusion compared to the standard 3 hours ischaemia followed by t hour of reperfusion.
The expectation that there would be significantly lower microvascular patency in the subjects
reperfused for t hour was not confirmed. This study suggests that 3 hours of ischaemia
followed by t hour of reperfusion with "unmodified" blood, and 4 houts of ischaemia are
periods of injury resulting in irreversible microvascular occlusions in 30-50Vo of cerebral
microvessels. Certainly a study of patency with 3 hours of ischaemia and no reperfusion
should be performed to compare with 3 hours ischaemia and t hour reperfusion. If the 3 hour
ischaemia with no reperfusion also showed 30-50Vo microvascular occlusions, a more
rewarding paradigm would be a2 hour peliod of MCA occlusion followed by varying periods
of reperfusion (such as 0, I or 2, 4 and 24 hours). lf a 2 hour period of ischaemia without a
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period of reperfusion resulted in a high percentage (80-1007o) of microvascular patency on
the ischaemic side, this would provide a useful baseline for studying percentage reflow
associated with variable periods of reperfusion, and the effects of agents blocking leukocyte
adhesion of platelet aggregation.
The second project involved studying the novel cyclic RGD peptide TP9201 in this model.
This peptide blocks integrin crllbp3 binding between platelets. Initial pharmacokinetic and
pharmacodynamic studies were undertaken to ensure that this peptide could be safely infused
into primates (and hence humans), to determine the half-life and drug concentration required
to inhibit platelet aggregation.
Following acquisition of these data, the drug was used for a series of 3 hour ischaemia / 1
hour reperfusion experiments. These experiments resulted in 3 of 4 subjects sustaining
moderate to large haemorrhages in the reperfused basal ganglia. Microvascular patency was
higher in the one subject who did not sustain a haemorrhage than in the control 3 hour
ischaemia/l hour reperfusion group, but greater than I007o on the ischaemic side for each
vessel size in each animal sustaining haemorrhage. These results are thus highly likely to be
due to artefact. Further studies (see areas for future research) ought to be undertaken prior to
use of this drug in human subjects.
The second aspect of reperfusion injury studied was endothelial modulation of the
coagulation system during reperfusion following focal cerebral ischaemia. Exposure of
cultured endothelial cells to hypoxia increases transmembrane permeability (Shreeniwas et al,
1991), stimulates type I Plasminogen activator inhibitor (PAI-1) synthesis (Lynch et al, 1988)
and activates coagulation factor X (Ogawa et al, 1990). In contrast with these data, systemic
tPA activity has been found to be elevated in severe peripheral ischaemia in humans
(Schneiderman et al, 1991).
During reperfusion, intravascular fibrin is generated from fibrinogen by thrombin in the
presence of TF (Drake et al, 1989), or activated platelets (Roth, 1992). Thrombin is
generated when platelets are activated by exposure to intramulal collagen or platelet
activating factor (which is generated by ischaemic endothelium). Activated leukocytes can
also stimulate thrombin formation (Sugama and Malik, 1992).
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Clearly, a time-dependent study of TF, tPA and PAI-1 gene expression by endothelium in-
vivo during reperfusion would provide invaluable information which could be used in
developing adjuvant strategies in the management of stroke. The technique of in-situ
hybridisation is a powerful tool which allows cellular localisation of specific mRNA
expression in tissue sections and is ideally suited to studying endothelial behaviour during
reperfusion.
Whitst no definitive results have thus far been obtained, considerable expertise has been
acquired in molecular techniques which can be readily developed with expert help to obtain
useful results.
Successful subcloning of tPA and TF DNA, bacterial transformation and DNA sequencing
have been performed. RNA plobe pleparation and hyblidisation with pteservation of tissue
morphology has been achieved. The final problem to be overcome is non-specific binding for
which a series of modifications and checks have not eliminated. Further work on this
problem is envisaged.
5.2 Future directions
The results of the microvascular patency studies suggest that several further studies should be
considered. The patency data from the 3 hour ischaemia / 1 hour reperfusion versus 4 hour
ischaemia support a change of paradigm to a shorter period of ischaemia followed by variable
time points of reperfusion such as 0, 1, 4 and 24 hours. A shorter period of ischaemia should
result in a percentage reflow of 80-1007o when no repetfusion period occurs, progressively
decreasing with increased periods of reperfusion as activated leukocytes adhere to post-
capillary venules and intravascular fibrin is deposited. Data acquired from these experiments
would generate baseline patency rates for studying the effects of adjunctive agents (such as
inhibitors of platelet aggregation, antibodies or peptides blocking leukocyte adhesion, e.g. P-
selectin antibody or sialyl Lewisx, and thrombolyic agents)
The use of TP9201 could either be abandoned, or re-studied at a lower dose. A further small
number of animals (N=2) could be infused fol pharmacokinetic and pharmacodynamic
studies at a lower dose which inhibits platelet aggregation without a significant increase in
bleeding time. Once such a dose has been decided upon, the experiments could be repeated,
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probably using a 2 hour ischaemia and an adequate period of reperfusion paradigm (at least 8
hours, as discussed in Chapter 3) if inhibition of intravascular platelet aggregation is to result
in significant improvement in microvascular patency.
Further refinement of the in-situ hybridisation technique will allow the use of brain specimen
blocks in studying the behaviour of brain endothelium, astrocytes and neurones during
reperfusion. In addition to studying mRNA activity of TF and tPA, cellular expression and
regulation of cytokine (e.g. interleukins and TNF) and cell adhesion molecule (e.g. E-selectin
and ICAM-I) could readily be studied in a time-dependent manner.
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Appendix 1 PRIMATE NEUROLOGICAL EXAMINATION












Normal - does not favour either side





Aware of surroundings, moves in response to examiners















Appendix 2 PHOTOGRAPHS OF CORONAL SECTIONS OF
BRAIN
Animal # 175
Haemorrhage in right basal ganglia
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Animal # L76




Ischaemic right basal ganglia
l?,o
Animal # 207
Ischaemic right basal ganglia
721.
Animal # 234




Ischaemic right basal ganglia
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Animal # 237
Hacmorrhage in right basal ganglia
PA
Animal # 238
Haemorrhage in right basal ganglia
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Appendix 3 IN-SITU HYBRIDISATION PROTOCOLS
3.1 Transformation
cDNA of interest in E. coli (stored in 50% glycerol at -70"C) picked up by scraper and placed
in 10 mls of E. coli growth medium (with ampicillin + tetlacycline) and placed in
shaker/incubator overnight (37"C)
ampicillin - 50 pg/ml
tetracycline - 12.5 pglmt
3.2 Ptasmid Purification (Miniprep Kit - Promega)
1. Pellet 1-3 ml of cell solution by centrlfugation (3000 RPM for 7 minutes).
2. Resuspend the cell pellet in 200 pl of "cell resuspension solution".
3. Transfer cells to a microcentrifuge tube (1.5 ml).
4. Add 200 pl of "cell lysis solution" and mix by inverting several times. Solution
should clear.
5. Add 200 pl "neutralization solution" and mix.
6. Spin in a microcentrifuge at 14,000 for 15 minutes.
7. Decant cleared supernatant to a new microcentrifuge tube, and discard precipitate.
8. For each miniprep Add 1 ml of "Magic Minipreps DNA Purification Resin" to the
supernatant from step 7 and mix by inverting the tube.
9. For each miniprep, use one Magic Minipreps mini-column. Attach a 3 ml disposable
syringe barrel to the luer-lock extension of each mini-column.
10. Decant the Magic Minipreps DNA Pulifîcation Resin containing the bound DNA into
the syringe barrel. Insert the syringe plunger and gently push the slulry into the mini-column.
11. Wash the mini-column with 2 ml Column Wash solution by removing the mini-
column from the syringe and taking up the solution in the syringe. Reattach the syringe to the
mini-column and fently push the Column Wash Solution through the mini-column with the
syringe plunger.
Important: The Column Wash Solution is NOT supplied with ethanol. Prior to
use, sufficient absolute ethanol must be added to the Column V/ash Solution to
bring the final concentration to 50% (v/v).
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12. Transfer the mini-column to a microcentrifuge tube, and place in a microcentrifuge. Spin
the mini-column for 20 seconds to dry the resin.
13. Transfer the mini-column to a new microcentrifuge tube.
14. To elute the plasmid DNA, add to the mini-column 50 pl of DEPC tleated water or TE
buffer heated to 65-70'C.
15. Spin the microcentrifuge tube containing the mini-column for 20 seconds in a
microcentrifuge. Remove and discard the mini-column store. Plasmid DNA in a
microcentrifuge tube -20"C. Each Magic Minipreps DNA isolation will yield up to 10lrg of
plasmid DNA.
NOTE: The yield of plasmid DNA is dependent on the plasmid copy number. The
plasmid DNA is ready for immediate use in any molecular biology procedure.
3.3 Linearization of DNA
plasmid DNA
10 x restriction buffer
Appropriate Restriction Enzyme
1.5 Lrg
2 ¡t"l (if total vol 20 ¡rl)
15-25 units 1- 2 pl) (no more than 70Vo of total
volume)
to 20 pl final volumeM.B. H2O
Incubate at37"C for 2 hours.
Add 6x marker. Heat to 56"C for 2 minutes.
Run TAE or TBE gel approximately 50 volts for 2-3 houts
Blunting 3' end of cDNA (if necessary)
Heat DNA to 55"C for 5 minutes.
Add Klenow 1 unill pg DNA and 0.5 mM each dNTP/ pg DNA-
Incubate at 30' C for 15 minutes, heat inactivateT5" for 10 minutes.




Gene Clean Protocol (DNA purification using glass milk)
Run TBE gel for 45-60 mins.
Turn on water bath to 56"C. Defiost glass milk.
Cut DNA out of gel under UV. Do it quickly (take <20 seconds so that DNA not
damaged).
Weigh gel (must be <0.4 g.)
Addz ¡rl NaI for each mg. agarose.
Melt agarose in waterbath =5 minutes (discard NaI if it is yellow).
Add 5 pl glass beads (I ILEI 1 pg DNA, but a minimum of 5 pl)
Ice for 5 minutes.
Spin 13K RPM 30 sec.
Discard supernatant.
Wash pellet 3x with cold NEW SOLUTION (200 pL) (10-50x vol). Resuspend pellet,
spin 10 seconds, discard supernatant, lepeat.
Do one dry spin.
Add 10 pl Depc water, mix with pipetæ tip.
Spin 20 sec 13K RPM.

















1.5 g Na Sulfite
100 ml HZO
Filter through Nalgene, 0.2 pm filter
Add 0.5 g Na Sulfite to saturate solution




10 ml IM Tris, pH7.4
1 ml0.5 M EDTA
20 ml 2.5 M NaCl
500 ml store -20"C
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3.5 DNA Agarose Gel





Per Well: 2ptL DNA
lpl- 6x Dye
3pL DEPC water
Preheat DNA samples at 65oC (2 min).
Spin 3K RPM I sec.
Run at 50V for 1-2 hours.
Take photo. Set camera on l1-1.
Maximum well volume: 10pL 30 well comb
60pL 10 well comb
3.6 Marker mix for DNA gels (Lambda/Hind III)
( use 8pL per well)
4ttL 2.5M NaCl
10t[ lM Tris (pH 7.5)
2ttL 0.5M EDTA
l00pl DNA
167¡tL 6x Ficoll dye
717lrl DEPC water
1 ml (2 x 500pL)














f . increases sample density
2. add colour, simplify well loading
3. migrates at predictable rate in waterlíVo Ficoll (type: Pharmacia)
TAE (Tris-Acetate)
48.4 g Tris base
11.42 mls glacial acetic acid
20 mls 0.5 M EDTA pH 8.0
make up to 1 litre
(use only for diagnostic gels - not for DNA extraction)
3.8 RNA gel
Note: Formaldehyde vapols are toxic. Use hood.
1. Prepare L.57o gel
1.0g molecular biology grade Agarose
60ml DEPC HZO
Heat to 60oC and stir
Add
7ml 10x MOPS
2.lml37Vo Formaldehyde (pH >4)
Mix with stir bar.
Pour gel. (Solidifies quickly) Set until cloudy (=20min)
Use 10 well comb (fits = 50pl on a good day)
2. Prepare samples
Premix: 4.5¡rl 10x MOPS
7 .9¡tl 377o Formtldehyde
22.5u1 Folmamide
34.9¡tI
10.1p1 Max. RNA (0.5 to 10pl)
TBE (Tris-borate)
108 g Tris base
55 g Boric acid
40 mls 0.5 M EDTA pH 8
make up to 1 litre
(5p1=5pg for Promega RNA Marker)
45.0p1 (use DEP water)
Mix, incubate 56"C for 15 min.
Add: 9pl Loading Buffer
9trl ErBr. (500pg/ml)
Mix, spin,load into gel.
3. Run gel. 5V/cm x 10 cm i.e.50V. 3h gives good resolution. 2h is OK.
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3.9 RNA Markers (Promega)
The following 8 bands are visualised in an ethidium- stained lVo formaldehyde gel / MOPS
running buffer with 2pl of the RNA' prepared in formaldehyde / MOPS buffer.















Transformation of bacteria (for subcloning)
Obtain bacterial strains (XLI Blue for tPA, NM522 for TF) for the plasmids in which
DNA inserted (pBSIIkS for tPA, PGEM for TF).
Add 40 ml of sterile LB medium to a sterile culture flask . Scrape 1 colony of
bacterial cells (above) with a sterilised metal loop and place in LB medium.
Put flask in shaking water bath at 37oC. Stop when medium has an O.D. of 0.3 to 0.5
at 600 nm (check small aliquot at 2 hours and then every half hour).
Spin cells at 2,500 g for 5 minutes at room temperature.
Gently resuspend pellet of cells in 4 mls of 50 ¡rM CaCl2. Bring up to 20 mls with 50
pM CaCl2 (cells now fragile).
Incubate for 30 minutes on ice (cells now "cotnpetent").
Centrifuge cells for 5 minutes at2,500 g at 4oC. Resuspend in 4 mls ice-cold CaCl2.
Store cells overnight at 4oC.
Store in 30Vo glycerol if longer term storage (-70"C).if longer term storage required.
In a4 ml snap-top sterile tube, add about 0.1 Ltg of plasmid DNA to 200 pl of
competent cells.
Incubate on ice for 30 minutes.
Heat shock cells by transferring tube to a37oC water bath for 5 minutes.











Use sterilised bent glass rod to spread Xgal (800p9) and IPTG (800pg) on each LB
agar plate containing ampicillin * ætracycline (only for XLI Blue).
Add 100-200pL of transformed cells to each plate and spread evenly.
Incubate at 37"C overnight.
All colonies growing should contain plasmid, as antibiotic resistance is contained in
plasmid. White colonies contain the insert in the plasmid, otherwise the blue colour
is expressed.
Remove single colonies of interest (usually white) next day, with a sterile loop and





3.12 Transcription Protocol - probe preparation
20 ¡tL of 35S-UTP (10 pCi / pL) Activity grearer than 1000 ¡rCi/mmol. (10 pM. UTP)
speed vac dry (45 min, medium dlying late)
(Substituæ 1 ¡rL rUTP stock for "cold" RNA synthesis)
Premix 10.5 l,:
4 pL 5x Transcliption Buffer
2 ttL 100 mM DTT
0.5 pL RNasin (=RNasin inhibitor, 20 units)
4 pL INTP mix (2.5 mM ea) ( 1:1: 1 : I ATP, GTP, CTP,
water)
(may also want to try 1ì, 100pM rUTP - some protocols use 100pM
cold + UTP)
To premix add:
:1 [rL Linearized template (0.2 ttg - I ttg) (gene cleaned)
1 pL Polymerase (15-20 units)
make up to 20 pL / reaction with DEPC water.
Incubate 37-40'C l1l2 - 2 hours (Promega suggests for full length
transcripts use 22oC )
NOTE: limiting nucleotide should be greater than 12 pM but less than 24 ¡lM (UTP in this
case)
t32
3.13 Remove DNA Template
1. Add RQl RNase-free DNase. I unilpg template. Use 5 pL. Incubate 15 min
370C.
2. Add 20 pg tRNA. Use 2 pL Wheat tRNA solution.
3. Bring volume up to 100 pL, with DEPC HZO.
4. Extract with 1 volume (100 pL) SSC saturated phenol: chloroform: isoamyl alcohol
25:24:I. Vortex. Spin 13K RPM 2 min.
5. Take upper aqueous phase (with RNA) and add to "new" tube. To original tube add
chloroform: isoamyl alcohol 1 volume (100 ttl-) (24:l). Vortex. Spin 13K RPM 2
min. Transfer upper phase to new tube.
6. Remove unincotporated nucleotides and concentrate RNA
a. Add ll2 vol (50pL) 7.5M NH4AC (pH should be =6)
b. Add 2.5 vol (250 pL) EIOH. Mix. Store -80oC 30 min.
c. Spin 13 K RPM 5 min.
d. Discard supernatant by shaking liquid out.
e. Resuspend in 100 pL 1M NH4AC . Mix.
f. Add 2.5 vol (250 pL) EIOH. Mix. Store -80oC 30 min.
g. Spin 13 K RPM 5 min.
h. Shake off supernatant.
i. Wash pellet with 500 ¡tL707o EIOH. (Store -80oC until ready to use)
j. Spin 5 min 13K RPM. Discard supematant being careful not to throw pellet
away also.
k. Air dry 10 min
l. Resuspend pellet in DEPC water (10 pL). Use or store at -70oC for up to 4
weeks if necessary.
7 - Run RNA on denaturing RNA gel to check transcription (=lLrL) and expose overnight
on XR plate.
8. Check for incorporation by counting scintillations.
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3.14 Slide preparation
Cleaning slides for in-situ hybridisation
1. Place slides in racks.
2. Dip in lVo IM HCI in 707oEtOH. (For in-situ use DEPC HZO) 30 min
3. Dip in DEPC HZO. 30 min
4. Dip in 95Vo E;IO}J (240 ml EIOH I 250 mI) 30 min
5. Put in oven 70"C until dry.
Cleaning coverslips (in-situ)
Soak in 10% Nitric Acid Bath lh. (36m1 of 707o HNO¡ I 250n1DEPC HZO)
Rinse with DEPC HZO.
Allow to dry.
Autoclave 30 min. Drytime 10 min.
Chrom-Alum Slide preparation
1. Add 0.1g gelatin (Sigma) to 250 ml DEPC HZO. Dissolve by heating to 60'C .
2. Add 0.lg Chromium K2SO4. (ACS). I2HZO- turns blue.
3. Dip cleaned slides (see above). Warm solution for 30 seconds.
4. Dry overnight3ToC. Keep covered with foil.
5. Return slides to box. If not dry, will stick.
Poly-L-lysine slide preparation
Dip cleaned slides in 50 pg poly-L-lysine in 10 pM TRIS pH 8 for 30 minutes.




In-situ hybridization Protocol - Day 1.
Make 4Vo paraformaldehyde in PBS with millipore water - heat to 65oC in
fume hood. Cool and filter. Store at 4oC.
Cut sections (20 pm). Mount on Poly-l-lysine coated slides. Air dry 30 min. 20' at
RT
Fix with paraformaldehyde at 4oC







Prepare Proteinase K mix.
Rinse with PBS (300 mL) for 15'at RT
Prepare triethanolamine (used in step 8)
Proteinase K digestion (300 mL) lpg/ml in buffer incubate for 5-20
minutes (see text)
Use 15 mL stock/300 mL Proteinase K buffer
Rinse in PBS (300mL) for 15'at RT
Dip 2x DEPC H2O (300mL)
Acetylate. Make 0.1 M triethanolamine-HCl (pH8.0) (5.6gl300ml DEPC
Hzo)
Add Acetic Anhydride . 7 50¡t"Ll 300mL triethanolamine
Acetylation blocks positive amino acid groups (reduces electrostatic
binding).
Add slides to step 8 mix. Gently shake. Incubate for 10 minutes
at RT.
Wash in PBS (300 mL) for 15 minutes at RT
Postfix in 4Vo Paraformaldehyde/PBs (300 mL) for 5' at RT
Prepare prehybridisation m ix
Dehydrate- 70Vo EIOH for 4' at RT
907o EIOH for 4' at RT
I007o EtOH for 4' at RT
Air dry
Prehybridisation. Apply 200 mLlsection. Incubate for t hour at. 45"C
Preheat extra prehybridisation mix to 45"C as well.
Hybridisation Step.
Make up hybridisation mix by adding I07o dexîan by weight to prehybridisation mix.
Dissolve dextran. (difhcult). Add enough RNA probe to give approximately 5 x 105
counts of probe per 150pL of hybridisation mix.(each section) Heat RNA to 80 to
95"C for 5 minutes to "melt" RNA. Dlain prehybridisaton solution from slides, but do
not let them dry.
Apply 150pL probe/section .
Apply coverslips

























In-situ hybridization Protocol - Day 2.
Preheat TE buffer and RNase buffer at37oC
Remove coverslips from incubated slides in 4 x SSC/10 mM DTT.
Wash in 4 x SSC/10 mM DTT for 5 minutes RT
Wash in 4 x SSC10 mM DTT 10 min RT
Wash in 4 x SSC/10 mM DTT 10 min RT
RNAse treatment: 20 ¡tglml in 0.5M NaCVI xTE buffer (keep in special Wheaton
dish) 30' 37"C
Rinse 1 x TE / l0 mM p-mercaptoel.hanol 30' 37"C
Rinse 1 x TE / 10 mM B-mercaptoethanol 30' 37"C
Rinse 2 x SSC / 10 mM p-mercaptoethanol 30' RT
Rinse 2 x SSC / 10 mM p-mercaptoethanol 30' RT
Rinse 0.1 x SSC/ l0 mM p-mercaptoethanol 30' 45"C
Dehydrate 707o ethanol / 0.3 M NH4Ac 4' RT
907o ethanol / 0.3 M NH4Ac 4' RT
l00Vo ethanol / 0.3 M NH4Ac 4' RT
Air dry
Place XR plate on top of slides and store 1-3 days.
Develop film to check for activity and background and coat with photographic
emulsion.
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3.Ll Emulsion Coating of Slides
1. Use a sodium vapor lamp in the dark room which is a minimum of 4 feet away from
your wolking surface.
2. Dilute Ilford K-5 emulsion 1:1 with milliporc water and place in a 45oC 'water bath for
30-45 minutes. The container of emulsion should be covered during the melting period. An
alternative is to cover the entire water bath.
3. After melting the mixture, gently stir the emulsion with either a wood stick or a
porcelain spatula. The emulsion should be thoroughly mixed with the water"
4. Using the corner of a tissue, carefully go around the edge of the surface of the
emulsion to remove any bubbles.
136
5. Carefully transfer the emulsion to the dipping chamber which should be seated in the
45"C water bath.
6. Dip several blank slides in the emulsion to remove bubbles. Slides should be dipped
straight in and out without agitation.
7. Dip experimental slides in the above fashion. After each slide is dipped, wipe the
emulsion off the back side of the slide. This is best done with a kimwipe of a paper towel.
Use a fresh kimwipe for each slide.
8. Place the dipped slides on a plexiglass slide rack ( about 40o angle) and allow them to
drain on paper towels.
9. Transfer the slides to black light-tight boxes and allow the emulsion to dry 2-3 hours.
10. Place the slides in black slide boxes which contain 2-3 dessicant capsules (humicaps).
Tape the boxes with black electrical tape, wrap the boxes in foil. label. and place in
refrigerator (4'C), no light bulb, for incubation period.
3.18
1.
Development of Emulsion Dipped Slides
Bring the slides to room temperature prior to development. (Take the black boxes
from the refrigerator and leave at room temperature sealed and with the proper safe
light on)
Use all developing, rinsing and fixing solutions at 15"C.
Develop as follows:
D-19 undiluted for 2.5 min
waterwashxlmin
30% Na Thiosulfate (1) x 10 min.
307o Na Thiosulfate (2) x 10 min.
running water for 60 min.
If the slides are not cleared at this point, i.e. there is a residue of gelatin from the
emulsion, dehydrate and rehydrate slides plior to counterstaining.
Suggested counterstain is freshly filteled Richardson Stain for 3-4 min, several
water rinses until clear,






20 mls lM Tris HCI (pH 7.6)
4 mls 0.5 M EDTA
make up to 300 mls with DEPC water
Prehybridisation solution (to make 1 ml)
2.5M NaCl I20],,
3M NaAc (pH 5.2) 6.7L




20 mglml tRNA 12.5ì\
10 mg/ml DNA 25ì,,
207o SDS 5ì,
make up 1 ml with DEPC water
Hybridisation solution
Prehybridisation solution + I07o Dextran dissolved at 45oC.
Probe added to give = 106 cpm/section i.e. 106 cpm/150 pl
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Appendix 4 IMMUNOHISTOCHEMICAL EXPERIMENTS
Appendix 4.1
Focal ischaemia/reperfusion experiments















































































Focal ischaemia /reperfusion experiments

























































Focal ischaemi a experiments


























































Appendix 5 DNA SEQUENCES
Appendix 5.1
Sequence of sub-clone of Tissue Factor pJH24












Sequence of sub-clone of Tissue Factor pJH24











Sequence of sub-clone of tPA
Using M13 promotor (T7)
CGTNATACGACTCACTATAGGGCGAATTGGAGCTCCACCGNGGTGGCGGT
T7 siæ on pBS IIKS
CGCTCTAGAACTAGTGGATCCCCCG G G CTGCAGG-AATTC CATGATCCTGA
lupao+ of tPA
TAGGCAAGGTTTACACAGCACAGAACC CCAGTGCCCAG GCACTGGGCCTG
GGTAAACATNATTACTGNCG GAATCCTGATGG G G ATG CCAAG CCCTGNTG
TCACGTNCTGATGAACCGCAGGCTGACGTGGGAGTACTNTGATGTGNCCT
CCTGCTCCACCTGNGGNTCTGAGAC AGTAC AGACAG CCTCAG
r45
Appendix 5.4
Sequence of sub-clone of tPA
Using M13r promotor (T3)
GGGAACAAAAGCTGGGTACCGGG CCCCCC CTCGAGGTCGACGGTATC GAT
T3 site on pBSII KS
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